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ABSTRACT 
Khue Gia Nguyen: Effect of heparin on the immunobiology of interleukin-12  
(Under the direction of David Alexander Zaharoff) 
IL-12 is a potent pro-inflammatory cytokine that plays a central role in cellular immunity. 
Recently, we have shown that IL-12 is a specific heparin-binding protein. However, the 
interaction of heparin and IL-12 at the molecular level and the mechanisms by which heparin 
modulates the biological functions of IL-12 are unknown. For the first time, we described the 
unique ability of heparin to enhance the bioactivity of IL-12. Heparin was found to enhance 
binding of IL-12 to cell surfaces while modestly protecting the cytokine from proteolytic 
degradation. An exploration of critical heparin characteristics revealed that IL-12 binding and 
activity increased were dependent on heparin chain length and sulfation level. Based on our 
bioactivity data, we developed a model of stabilization showing that heparin likely serves as a 
co-receptor that enhances the interaction of IL-12 with its subunit receptors. Finally, we 
examined the effect of heparin on IL-12 bioactivity in IL-12R1 deficient cells. In both PBMCs 
isolated from patients of Mendelian susceptibility to mycobacterial diseases (MSMD) and IL-
12R1 mutant NK-92MI cell line, heparin was found to partially recover IL-12 signaling as 
measured via IFN- production. Taken together, these studies define a new role for heparin as a 
modulator of the immunobiology of IL-12 and potentially other IL-12 family cytokines.  
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CHAPTER 1: INTRODUCTION 
1.1. The structure and production of IL-12 
IL-12 is a potent pro-inflammatory cytokine that plays a central role in cellular immunity. 
IL-12 is composed of two subunits, p35 and p40, that are linked by three disulfide bridges to 
form a p70 heterodimer (1-4). The structure of p35 is similar to other single-chain cytokines, 
such as IL-6, whereas p40 shares homology to the hematopoietic receptor family, particularly the 
extracellular domain of the IL-6R chain (5). It has been suggested, therefore, that IL-12 arose 
from a combination of an IL-6 family member and its receptor (6). 
 p35 is constitutively expressed by various cell types while the expression of p40 is 
induced mainly by TLR ligands and generally limited to antigen presenting cells, such as 
dendritic cells, monocytes and macrophages (7). p40 is produced in excess while p35 is only 
secreted when linked to the p40 chain to form a complete IL-12 molecule (3). p40 is secreted in 
two forms, a monomer and a disulfide linked homodimer (8). Both p40 monomer and p40 
homodimer have been shown to compete with IL-12 for binding to IL-12R (8-10). In mice, p40 
homodimers have been detected in vivo during inflammatory events and have been shown to 
antagonize the functions of IL-12 (11). p40 homodimers overexpressed in human cells have been 
shown to bind to IL-12R and act as an antagonist of IL-12 in Kit225/K6 cells, a human T cell 
line that expresses IL-12R (12). Heparin, a negatively charged GAG, was found to inhibit the 
antagonist activity of p40 monomer and p40 homodimer on IL-12 (Appendix 3). Unlike in mice, 
p40 homodimers have not been detected in humans or produced by non-transfected human cells 
even in the presence of large amounts of p40 monomer (13).  
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As mentioned above, IL-12 is mainly produced by phagocytic cells, such as monocytes, 
macrophages, neutrophils, microglia and DCs in response to TLR stimulation with structural or 
released components of bacteria, parasites, or fungi, including LPS, CpG oligonucleotides, 
bacterial DNA, or double-stranded RNA (14). For example, 2 research groups led by 
Mashayekhi and Reise-Sousa have shown that CD8α+ DCs are the first cell population to 
synthesize IL-12 in vivo in response to soluble extracts of Toxoplasma gondii or to LPS (15, 16). 
Other pathogens, such as Brucella abortus or CpG containing bacterial DNA, have been shown 
to trigger production of IL-12 by both CD8α+ and CD8α− DCs (17-19). In response to several 
types of viral infection, plasmacytoid DCs are another source of IL-12 (20). Macrophages and 
monocytes are strong producers of IL-12 in response to bacterial peptidoglycans (21, 22). 
The production of IL-12 is controlled by positive and negative feedback mechanisms. The 
diversity and quantity of TLRs expressed in phagocytic cells will determine the relative 
efficiency of IL-12 production in response to pathogenic components (23, 24). However, TLR 
stimulation alone is insufficient to maximize the production of IL-12. The presence of IFN- 
enhances IL-12 production by augmenting the transcription of both p40 and p35 (25, 26). IFN- 
functions as a positive feedback factor for IL-12 production in inflammation and TH1 responses. 
Interleukin-10 (IL-10), which is also induced by pathogenic stimulation, is immunosuppressive 
and inhibits p35 and p40 transcription (27). 
1.2. IL-12 receptors and signaling 
IL-12R consists of 2 receptor subunit chains, IL-12R1 and IL-12R2. The receptor 
subunits share similar morphologies with the type-I cytokine receptor superfamily and are 
homologous to gp130 (28). IL-12R1 binds p40 with a Kd of 6 nM, IL-12R2 binds p35 with a 
Kd of 5 nM while the p70 heterodimer binds both subunits with a Kd of 65 pM (29). IL-12R2, 
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normally expressed on NK cells and activated T cells, plays a vital role in triggering IL-12 
signaling (30). IL-12R2 is up-regulated by TH1-related cytokines and down-regulated by TH2-
related cytokines (31). IL-12R1, a type I transmembrane protein with a disulfide linked 
oligomer, is constitutively expressed at low levels in lymphocyte and can be upregulated by T 
cell activation (32). Upon the binding of IL-12 to IL-12R, IL-12 recruits 2 important kinases 
including JAK2 and TYK2. These kinases phosphorylate themselves and IL-12R leading to the 
recruitment of STAT3 and STAT4 to the intracellular domain of IL-12R. STAT3 and STAT4 
binds to the phosphorylated receptor and are phosphorylated by the activated JAK2 and TYK2. 
Phosphorylated STATs form dimers and translocate into the nucleus to induce expression of the 
transcription factor family of interferon regulatory factors. These transcription factors then 
regulate target genes that are important for the effector functions of TH1 cells (33-37).  
Individuals with defects in IL-12 signaling exhibit profound immunodeficiencies. In 
particular, patients with mutations in IL-12R1, IL-122 or TYK2 lack sufficient production of 
IFN-. These patients are unable to mount immune responses against intracellular infections (38, 
39). 
IL-12 has a number of proinflammatory biological functions. Chief among these is IL-
12’s ability to activate cell-mediated effectors, including NK, NKT and CD8+ T lymphocytes 
(40, 41). Specifically, IL-12 promotes the proliferation, cytotoxic activity and IFN- production 
of activated NK and CD8+ T cells. IL-12 also induces the differentiation of naïve CD4+ T 
lymphocytes into TH1 effectors that produce IFN- (42-45). In addition, IL-12 recruits NK cells 
to tissues by serving as a direct chemotactic factor (46). Furthermore, IL-12 has been found to 
mediate the activation of human and murine B cells (47, 48). B lymphocytes can be developed 
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into IFN- producing cells when they are synergically stimulated with IL-12 and IL-18 in vivo 
(49). 
1.3. IL-12-based cancer immunotherapy 
1.3.1. The use of IL-12 as an antitumor reagent 
The pleiotropic functions of IL-12 which drive cellular immunity support its exploration 
as an antitumor agent. In addition to the biological activities of IL-12 mentioned in the previous 
section, IFN-, which is strongly induced by IL-12 has been shown to be directly 
cytotoxic/cytostatic to some tumor cells, upregulates MHC class I on tumor cells, has anti-
angiogenic activity, and enhances T cell infiltration into tumors (50-53). Not surprisingly then, in 
numerous preclinical studies, the systemic administration of recombinant IL-12 triggers tumor 
regression and increases survival rate in mice bearing a wide range of transplantable, 
spontaneous, or carcinogen-induced tumors (54-57). Antitumor effects of IL-12 were found to be 
largely dependent on CD8+ T cells, NK and NK T cells (55, 58, 59).  
In clinical studies, IL-12 has been evaluated as an experimental treatment for numerous 
malignancies (60-70). Unfortunately, the efficacy of IL-12 at tolerated doses was minimal (61, 
62, 65). Atkins and colleagues were the first to employ IL-12 immunotherapy in a clinical trial 
(60). This phase I study enrolled 40 patients, including 20 with renal cancer and 12 with 
melanoma, to investigate intravenous administration of recombinant hIL-12. One melanoma 
patient had a transient complete response and one renal cancer patient had a partial response with 
recombinant hIL-12 (60). In a separate study, ten pretreated patients with advanced melanoma 
were enrolled in a pilot study of subcutaneous recombinant hIL-12 (61). A fixed dose of 
recombinant hIL-12 (0.5 g/kg) was given to patients on days 1, 8, and 15 for two sequential 
cycles of 28 days. No partial or complete responses were reported. Minor tumor shrinkages 
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involving some subcutaneous metastases and hepatic metastases were observed.(61). In yet 
another study in melanoma patients, the administration of IL-12 was found to induce a striking 
burst, in the periphery, of HLA-restricted CTL precursors directed to autologous tumors and to 
multiple immunogenic tumor-associated antigens (71). Significantly, the infiltration of CD8+ T 
cells with a memory and cytolytic phenotype was identified in posttreatment metastatic lesions, 
but not in pretreatment metastatic lesions of three patients (71). IL-12 has induced more 
productive antitumor responses against cutaneous T cell lymphoma variants (70), AIDS-related 
Kaposi sarcoma (76) and non–Hodgkin’s lymphoma (77), however, it has never progressed past 
phase II studies.  
Although IL-12 has demonstrated robust antitumor activity in preclinical studies and 
potent immune-stimulating potential in humans, systemic administrations of IL-12 have been 
shown to be exceedingly toxic. In a phase II trial sponsored by Genetics Institute, a maximal 
dose of 0.5 g/kg per day resulted in severe side effects in 12 out of 17 enrolled patients and the 
deaths of two patients (72). Interestingly, the dose of 0.5 g/kg IL-12 per day was found to be 
well-tolerated in patients that were enrolled in a previous phase I study. A difference in dosing 
schedule accounted for the differences in toxicity between the phase I and phase II trials. In the 
phase I trial, a single tester dose of IL-12 was administered one week before a multiple-dose 
regimen. The tester dose was found to blunt the toxicity associated with the multiple doses (73). 
1.3.2. Advances of IL-12 based cancer immunotherapy 
Due to the toxic effects of IL-12, recent efforts have focused on delivery strategies with 
potential to target tumors directly and/or restrict the systemic dissemination of IL-12. (59, 60). 
Numerous technologies involving gene delivery, IL-12-encapsulation, injectable hydrogels, and 
targeted IL-12-fusion proteins are under investigation (54, 61-66).  
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1.3.2.1. Gene-based delivery of IL-12 
Gene-based delivery of IL-12 is attractive for several reasons. First, in vivo expression of 
IL-12 can provide sustained cytokine levels that overcomes the need for multiple administrations 
due to rapid IL-12 clearance. Second, if the plasmid containing IL-12 gene is locally delivered, 
i.e. directly within a tumor, more of the IL-12 will be retained at the desired site/tissue compared 
to systemic delivery of recombinant IL-12. High local levels of IL-12 are capable of triggering 
antitumor responses. Intratumoral (i.t.) injections of plasmid DNA encoding IL-12 have 
demonstrated significant antitumor activity against melanoma (74), colorectal adenocarcinoma 
(75-78) and renal cell carcinoma (76) in preclinical models. In the clinic, i.t. injections of IL-12 
plasmid were found to reduce the size of treated lesions by at least 30% in 5 of 12 patients 
enrolled in a Phase I/IB study (79). In another Phase I/II trial, 3 of 9 and 8 of 9 patients with 
stage IV malignant melanoma experienced clinical and local responses, respectively, following 
intralesional injections with IL-12 plasmid (80). IL-12 plasmid injections were well tolerated as 
no patient in either study experienced a significant treatment related adverse event.  
Several technologies are under investigation to enhance the delivery and antitumor 
activity of IL-12-encoding DNA. The application of pulsed, high electric fields to facilitate 
cellular uptake and expression of a therapeutic gene is called electro-gene therapy (EGT). EGT 
with cytokine-encoding genes injected i.t. has been explored in range of tumor models (81-85); 
SCCVII (85), CT26 (86), RENCA (86-88). EGT with i.t. IL-12 plasmid induced tumor 
regression in up to 80% of mice, whereas i.t. injections of IL-12 plasmid alone delayed but could 
not eliminate primary tumors (84). In other tumor models, EGT with i.t. IL-12 plasmid 
suppressed the growth of murine SA-1 sarcomas leading to complete regression in approximately 
50-90% of treated mice (87, 89). Importantly, i.t. IL-12 EGT was able to inhibit the growth of 
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distant untreated tumors (89). In a study using dogs presenting with mast cell tumors, i.t. IL-12 
EGT resulted in a 13 to 83% reduction in tumor volume (90). Treated nodules displayed 
increases in leukocytic inflammation and decreases in the number of malignant mast cells (90). 
In beagles with canine transmissible venereal tumors (CTVTs), i.t. IL-12 plasmid followed by 
electroporation induced complete regression of treated lesions (91). Contralateral untreated 
tumors were also significantly inhibited. Serum IL-12 peaked 7 days after treatment however, 
blood chemistries and cell counts were not different from those of control dogs (91). 
Reports conflict on whether i.t. IL-12 EGT does (89-94) or does not (83, 87, 95) produce 
significant increases in serum IL-12 and IFN-. One study that i.t. IL-12 EGT of subcutaneous 
(s.c.) MH134 hepatocellular carcinomas resulted in elevated serum IL-12 and IFN- for at least 
one month (93). 
Recently, a Phase I study using electroporation immediately following i.t. injection of IL-
12 plasmid demonstrated that 53% of patients with stage III or IV melanoma experienced a 
systemic response defined as either stable disease or regression of untreated lesions (96). Most 
notably, 2 of 19 patients showed complete regression of all metastases. The importance of 
electric-field assisted delivery of plasmid was obvious as the aforementioned Phase I/IB study by 
Mahvi et al. used the same IL-12 vector without electric-field but found no differences in 
untreated lesions (79).. 
Complexes of polymers or lipids with DNA, are under investigation to enhance the 
delivery and transfection efficiency of cytokine-encoding plasmids. IL-12 plasmid/PVP 
polyplexes eliminated half of RENCA and CT26 tumors following 4 i.t. injections (97). 
Antitumor responses were dependent on CD8+ T cell. Overt signs of toxicity normally associated 
with systemic IL-12 administration were not observed. IL-12/PVP was more effective than 
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IFN/PVP in controlling preclinical tumors while the combination of IL-12/PVP and IFN/PVP 
synergized to eliminate 100% of RENCA and 50% of CT26 tumors (98). Plasmids complexed 
with poly-a-(4-aminobutyl)-L-glycolic acid (PAGA) enhanced transfection efficiency and 
expression of IL-12 in vitro and in vivo (77, 99). However, T cell infiltration of injected CT26 
colon adenocarcinomas and antitumor activities following repeated injections of PAGA/IL-12 
and naked IL-12 were similar (77). IL-12 DNA complexed with a cationic lipid and injected i.t. 
was found to inhibit and eliminate CT26 and RENCA tumors and protected mice from re-
challenge (76). Interesting, a direct comparison between naked IL-12 DNA and lipid complexed 
IL-12 DNA revealed no difference in antitumor activity (76). 
Currently, there are 5 ongoing clinical trials evaluating gene-based delivery of IL-12 in 
cancer treatment that are listed on the cllinicaltrials.gov website provided by the National Library 
of Medicine at the National Institutes of Health (NCT03281382, NCT02555397, NCT02531425, 
NCT03132675, NCT03567720. Key words used for searching included “IL-12 gene therapy”, 
“cancer”). 
Although no serious IL-12-related toxicities have been reported in any of the above 
studies, the use of IL-12 DNA raises concerns over the possibilities of uncontrolled IL-12 
production and genetic recombination. In addition, a major disadvantage of this approach is the 
inherent variability of IL-12 transfection in vivo.  
1.3.2.2 Oncolytic Viruses  
Oncolytic viruses expressing IL-12 have become a promising trend in cancer therapy. 
Recently, T-VEC, a genetically engineered herpes simplex virus producing GM-CSF, was the 
first oncolytic virus to receive by the FDA approval. Oncolytic viruses were first discovered in 
the late 19th century in cancer patients who simultaneously developed viral infections (100, 101). 
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Oncolytic viruses are able to selectively lyse cancer cells expressing low level of proteins that 
play important roles in both tumor suppression and viral infection, e.g. p53 protein. A genetically 
engineered HSV-1 expressing IL-12 is currently being tested in patients with 
recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma in a 
phase I study (102). In the study, M032 oncolytic HSV-1 was infused via a catheter at a single 
dose into tumor sites defined by magnetic resonance imaging. The results showed that M032 
oncolytic HSV-1 selectively infected and lysed tumor cells but not normal cells. Local secretion 
of IL-12 promoted specific antitumor responses at the tumor sites. In another study, oncolytic 
adenovirus encoding non-secreting IL-12 was effective in enhancing survival of animals bearing 
pancreatic tumors with no toxic side effect (103). Removing the signal peptide sequence of IL-12 
led to the accumulation of IL-12 inside cancer cells with minimal systemic release.  
1.3.2.3 Immunocytokines 
Immunocytokines, also known as antibody-cytokine fusion proteins, allow potentially 
toxic cytokines, such as IL-12, to be targeted to a tumor following systemic administration (104). 
The targeted element, usually an antibody fragment, can be engineered to bind tumor cells 
directly via mutant or overexpressed proteins or indirectly by targeting tumor vasculature or 
stromal components. 
The monoclonal antibody, BC-1, which recognizes the oncofetal fibronectin isoform, B-
FN. B-FN is highly expressed in tumor tissues but undetectable in normal adult tissues with the 
exception of endometrium (105). The immunocytokine, huBC1-IL12, is comprised of two 
molecules of IL-12 linked to each of the IgG heavy chains of BC-1 (105). Systemic 
administration of huBC1-IL12 was found to eliminate experimental PC3 metastases and suppress 
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the growth of multiple human tumor lines in immunocompromised mice more effectively than 
IL-12 alone (105). 
Another IL-12 fusion cytokine, NHS-IL12 capitalizes on the specificity of the NHS76 
antibody for extracellular DNA often found in necrotic tumors. NHS-IL12 has been shown to 
delay the growth of colorectal carcinomas in mice (106). Furthermore, tumor-bearing mice 
treated with NHS-IL12 developed CD8+ T cell responses against endogenous tumor antigens. In 
vivo imaging studies showed that NHS-IL12 was localized to flank tumors following a s.c. 
injection. NHS-IL12 is currently in Phase I clinical studies (NCT01417546) 
IL-12 has also been fused with the two F8 antibodies in single-chain variable fragment 
format specific to the extra domain A of fibronectin, a marker of tumor neovasculature (107). 
The novel molecule named IL-12-F8-F8 could be produced in mammalian cells at high yield. 
This immunocytokine inhibited tumor growth in three different murine tumor models, including 
subcutaneous teratocarcinoma, colon carcinoma, and lymphoma (107). 
One limitation of immunocytokines is that all targeting moieties are susceptible to non-
specific binding and distribution in normal, untargeted tissues. Radiolabeled NHS76 has been 
found in all major tissues in mice for 2-3 days after intravenous administration (108). In the case 
of neovasculature targeting moieties, angiogenesis is a normal process of wound healing and 
provides for atherosclerotic blood vessels. As a result, hypertension is a frequent adverse event 
for bevacizumab. Further complicating DNA-targeting agents, cancer patients have high levels 
of circulating cell-free DNA that is shed from tumors. It is not clear how circulating DNA 
impacts NHS targeting.  
Another concern is that systemically administered immunocytokines can still be expected 
to interact with immune cells in circulation. NK cells in particular are capable of producing large 
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amounts of IFN- which can lead to severe toxicities. The hope of this approach is that the use of 
targeting moieties may improve biodistribution enough to enhance IL-12’s therapeutic window.  
1.3.2.4 Sustained release platforms for localized delivery of recombinant IL-12 
Local administration of recombinant IL-12 protein is the most direct and most 
quantifiable strategy in terms of ensuring the accuracy and reproducibility of a delivered dose. 
However, recombinant cytokines disseminate rapidly from local injection sites (109). In fact, as 
mentioned above, s.c. injections of IL-12 caused dose-limiting toxicities in early clinical trials 
(62, 110). In order to maintain high levels of cytokines in the tumor microenvironment while 
minimizing systemic exposure, several delivery strategies are being investigated. The two most 
promising approaches are highlighted here.  
First, encapsulation of IL-12 in polycaprolactone:polylactic acid (PCL) and polylactic 
acid (PLA) microparticles has shown promise for i.t. immunotherapy of murine (111) and human 
tumors (112, 113). However, differences in antitumor efficacy have been noted in different 
models. For example, Egilmez et al. report that IL-12 encapsulated in PLA microspheres and 
injected i.t. can eradicate 70% of Line-1 tumors and 80% of CT26 tumors (111), however, others 
have found that the same immunotherapy regimen could not prevent the growth of B16 
melanoma (114) or MT-901 mammary carcinomas (115). Another concern of microsphere 
encapsulation of IL-12, is the required use of organic solvents during formulation. These 
solvents can denature IL-12 immediately or adversely affect long term storage if they are not 
completely removed. In fact, more than 80% of the bioactivity of IL-12 was lost when PLA/IL-
12 microsphere were stored for three weeks.  
The second approach involves development of injectable hydrogels and matrices capable 
of co-formulation with, and sustained, local release of IL-12. Our group has pioneered the use of 
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chitosan-based solutions and hydrogels for the local delivery of immunomodulatory agents, such 
as IL-12 (55, 116-118). Chitosan is a bioadhesive polysaccharide derived primarily from the 
exoskeletons of crustaceans. It is an unbranched copolymer of glucosamine and N-
acetylglucosamine units linked by (1-4) glycosidic bonds. Chitosan is non-toxic, biodegradable, 
and non-immunoreactive with an established safety profile in humans. It is used as a 
pharmaceutical excipient, a weight loss supplement and as active component of FDA-approved 
hemostatic dressings. In vivo, chitosan is safely degraded into excretable glucosamine and N-
acetylglucosamine fragments by lysozyme, glucosaminidase, lipase and other endogenous 
human enzymes. Importantly, chitosan is formulable in mild aqueous solutions which enables it 
to maintain bioactivities of fragile cytokines.  
Co-formulations of IL-12 with chitosan (CS/IL-12), when administered intratumorally, 
causes complete tumor regression in 80-100% of mice bearing established colorectal and 
pancreatic2 tumors (55). In an aggressive triple negative breast cancer model, neoadjuvant 
CS/IL-12 immunotherapy eliminated metastases in two-thirds of treated mice (117). In an 
orthotopic bladder cancer model, intravesical administration of CS/IL-12 induced complete 
tumor regression in 88-100% of mice. More importantly, in a dual tumor model, mice could be 
cured of a flank MB49 tumor if an orthotopic MB49 tumor was treated intravesically with 
CS/IL-12 (116, 118). In the absence of an orthotopic tumor, treated mice did not eliminate flank 
tumors. Thus, CS/IL-12 is capable of inducing an in situ vaccination leading to abscopal 
responses.  
Mechanistic studies revealed that CD8+ T cells were required for tumor regression while 
CD4+ T cells played a minor role. Tumors treated with CS/IL-12 became heavily infiltrated by 
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both CD4+ and CD8+ effector-memory T cells. Ongoing work with this platform is aimed at 
elucidating the neoantigen specificity of the cytotoxic T cell response.  
1.4. Heparin as a cytokine modulator  
Heparin is a naturally occurring polymer of the glycosaminoglycan (GAG) molecular 
family (119-121). Heparin is well known as the highest negatively charged polysaccharide of any 
known biological molecule (122). Heparin, which binds antithrombin, a critical protein in 
regulating coagulation, was the first anticoagulant drug to be discovered and approved for human 
useb (119). Additional biological functions of heparin include inhibition of angiogenesis and 
tumor growth (123, 124), antiviral activity (125-130), and inhibition of complement activation 
(131, 132). Heparin’s biological functions derive from its interaction with numerous proteins. 
The binding of proteins by heparin is mostly electrostatic, involving interactions between 
cationic groups of proteins with anionic sites on heparin. 
During the past several decades, more than 400 proteins, including many cytokines, have 
been shown to bind to heparin (133). Of particular interest to this dissertation research are the 
effects of heparin on the biological activities of interleukins. Heparin has been found to enhance 
the functions of some interleukins, while inhibiting others. On yet other interleukins, heparin has 
shown not any modulatory activity. These seemingly contradictory effects might be explained by 
the location of heparin binding sites on each interleukin. On the one hand, the binding of heparin 
may block the interaction of an interleukin with its receptor thus inhibiting interleukin 
bioactivity. On the other hand, heparin may cause oligomerization of interleukins leading to 
enhanced IL/ILR interactions, similar to FGF. Heparin may also stabilize the interaction of 
interleukin and its receptors to enhance interleukin signaling. The sections below will describe 
heparin or heparan sulfate-induced modulation of interleukin activity.  
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1.5. The binding of heparin-interleukin has no effect on interleukin bioactivity 
1.5.1. Interleukin 2 (IL-2) 
IL-2 is synthesized and secreted by antigen- or mitogen-activated T-cells. This 
glycoprotein promotes the proliferation of T cells and has an immunomodulatory effect on 
cytotoxic T-cells, natural killer cells, activated B-cells, and lymphokine activated cells (134, 
135). Najjam and colleagues showed a concentration-dependent interaction between human IL-2 
and heparin by ELISA (136). They reported two putative heparin binding sites on human IL-2. 
The first binding site consists of four basic amino acids, Lys48, Lys49, Lys54, and His55, 
whereas the other binding site contains a discontinuous region including Lys43, Lys64, Arg81, 
and Arg83. The binding of heparin to human IL-2 does not influence the latter’s bioactivity. 
Interestingly, the binding of heparin to human IL-2 was found to be dependent on heparin chain 
length while heparin did not bind to murine IL-2 (137). They also showed that the putative 
binding sites for heparin on IL-2 are well separated from the receptor binding sites (137). 
1.5.2. Interleukin 6 (IL-6) 
IL-6 plays diverse and important roles in various cell types (138). IL-6 is involved in host 
immune defense as well as modulation of growth and differentiation of many types of malignant 
tumors (139-141). Mummery and colleagues showed that IL-6 is a heparin-binding cytokine 
using an ELISA approach (142). It was suggested that the interaction with heparin could help 
localize pro-inflammatory IL-6 in or near a tissue of interest, thus favoring a paracrine 
mechanism of action. This study showed that the binding of heparin protects IL-6 from 
proteolytic degradation. By analyzing the effects of heparin on anti-IL-6 antibody binding, the 
authors concluded that heparin does not bind to epitopes that are critical for engagement of IL-
6R (142).  
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1.6. The binding of heparin-interleukin inhibits the bioactivity of interleukins 
1.6.1. Interleukin 4 (IL-4) 
IL-4 is a pleiotropic cytokine that was originally described as a B-cell growth factor 
(143). It produces both stimulatory and inhibitory effects on growth, differentiation and 
functional activity of B cells and T cells (144). Using different binding experiments, Lortat-
Jacob and colleagues investigated the interaction of IL-4 and an array of GAGs, including 
heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate (145). IL-4 exhibits a stronger 
binding interaction to heparin and heparan sulfate compared to less sulfated GAGs. In another 
study, the bioactivity of IL-4 was shown to be inhibited by heparin/heparan sulfate (146). The 
interaction of IL-4 and heparin was assessed by IL-4 binding to a heparin sepharose column. 
After incubation on a heparin sepharose column for 30 minutes, IL-4 was eluted and then tested 
on human peripheral blood monocytes. The effect of GAGs on IL-4 activity was then 
investigated by incubating IL-4 with dermatan sulfate and heparan sulfate (other GAGs that 
shared similar structure with heparin) for 30 minutes prior to treatment of IL-4 on human 
monocytes. The results revealed that IL-4-mediated suppression of LPS-induced TNF was 
significantly inhibited by these types of GAGs (146). 
1.6.2. Interleukin 7 (IL-7) 
IL-7 is a hematopoietic growth factor that influences development, proliferation and 
homeostasis of B and T cells (147). Clarke and colleagues proposed that heparin acts as a carrier 
for IL-7 to block its effect on target cells while preventing degradation from proteolysis (148). 
They found that heparin could inhibit the proliferation of an IL-7 dependent pre-B cell line (2E8) 
and protect IL-7 from serine protease digestion. 
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Zhang and colleagues dissected the binding interactions between heparin and murine and 
human IL-7 through surface resonance spectroscopy (149). The results showed that heparin had a 
greater affinity with human IL-7 when compared with murine IL-7. They believed that the 
degree of sulfation plays a key role in the interaction between IL-7 and heparin. As shown by the 
Borghesi group, heparan sulfate is required for the binding and bioactivity of IL-7 in pro-B cells 
(150). Other experiments in this study suggested that heparan sulfate proteoglycan expressed on 
stromal cell surfaces control the interaction of IL-7 to B-cell precursors. Therefore, they 
proposed that heparin and heparan sulfate proteoglycans may serve as a co-receptor of IL-7. 
1.6.3.  Interleukin 10 (IL-10) 
IL-10 is a cytokine produced by many cell types, including macrophages, activated T and 
B cells, B-cell lymphomas, keratinocytes, and mast cells. IL-10 is a pleiotropic cytokine that 
exhibits suppressive and stimulatory effects on the immune system (151). For instance, IL-10 
inhibits the expression of pro-inflammatory cytokines, including IL-12, secreted by macrophages 
and dendritic cells as well as antigen presentation. However, IL-10 enhances the proliferation 
and differentiation of B cells, murine thymocytes, mast cells, and megakaryocyte progenitor 
cells. The analyses of amino acid sequence have revealed that the C-terminus is rich in the basic 
amino acids arginine and lysine that serves as a binding site for GAGs (152). The expression of 
CD16 and CD64 stimulated by IL-10 on monocytes/macrophages could be inhibited by GAGs, 
such as soluble heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate in a 
concentration-dependent manner. Heparin and heparan sulfate were most effective with the half 
maximal inhibitory concentration (IC50) values of 100 to 500 mg/mL. Considerably higher 
concentrations of dermatan sulfate and chondroitin 4-sulfate were required with an IC50 of 2000 
to 5000 mg/mL, whereas chondroitin 6-sulfate was essentially inactive (152). 
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1.7. The binding of heparin-interleukin enhances the bioactivity of interleukins 
1.7.1. Interleukin 3 (IL-3) 
IL-3 was first discovered as a cytokine produced by concanavalin A-stimulated 
lymphocytes. IL-3 has multiple effects on proliferation and differentiation of many leukocytes 
(153, 154). Heparan sulfate, which is expressed on mouse bone marrow stroma, was found to 
adsorb and retain the biological activity of IL-3 (155). This discovery defined an important role 
for sulfated GAGs in the association of cytokines and hematopoietic stroma. The ability to bind 
and modulate IL-3 bioactivity of sulfated GAGs were investigated in another study that showed 
low doses of heparin enhance the bioactivity of IL-3 while high doses of heparin inhibit its 
bioactivity (156). This study also demonstrated that only heparin and heparan sulfate, not other 
GAGs, can modulate IL-3 activity.  
1.7.2. Interleukin 5 (IL-5) 
IL-5 plays an important role in eosinopoiesis and diseases associated with increased 
eosinophils (157, 158). IL-5 is secreted by TH2 cells and mast cells. Lipscombe and colleagues 
showed that IL-5 can bind to heparin and this interaction enhances the proliferation of an IL-5 
dependent cell line (159). In detail, the heparin-IL-5 interaction was detected using an ELISA-
based binding assay that showed human IL-5 has a stronger affinity to heparin when compared 
with murine IL-5. Furthermore, the bioactivity of IL-5, which was measured by the proliferation 
rate of the Baf-IL-5 cell line, was found to be increased by the addition of heparan sulfate. The 
interaction between IL-5 and GAGs including heparin, heparan sulfate and dermatan sulfate was 
explained not only by electrostatic interaction but also by the presence of L-iduronic acid (159). 
Additionally, it was found that ethylenediaminetetraacetate (EDTA) can inhibit the interaction 
between IL-5 and heparin; this inhibition is enhanced by insufficient concentrations of zinc ions. 
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1.7.3. Interleukin 8 (IL-8) 
IL-8 is a neutrophil chemotactic factor that is produced by multiple cell populations 
including monocytes, dermal fibroblasts, keratinocytes, endothelial cells, and hepatocytes (160, 
161). To study the interaction between heparin and IL-8, Möbius and colleagues conducted 
multi-disciplinary approaches involving site-directed mutagenesis, mass spectrometry, 
fluorescence and solution NMR spectroscopy as well as computer modeling (162). The results 
indicated that the interaction between heparin and IL-8 was mainly due to the amine groups of 
lysine and the guanidinium group of arginine side chains. Specifically, they identified Lys25, 
Lys69 and Lys72 were the most relevant binding sites of IL-8 with heparin. 
In another study, Spillmann and colleagues analyzed binding sequence for interaction 
between IL-8 and heparin/heparin sulfate (163). They found that the interaction of a monomer 
IL-8 and heparin/heparan sulfate is not strong enough to favor an interaction, while the dimeric 
form of IL-8 facilitates binding to sulfated domains of heparin/heparan sulfate. They suggested 
that the binding motif of IL-8 and heparan sulfate occurs in a horseshoe area over two 
antiparallel-oriented helical regions on the dimeric IL-8. 
Webb and colleagues showed the interaction of IL-8 with heparin would be affected 
when IL-8 structure was truncated (164). Removal of the N-terminal region prior the first 
cysteine, which was the IL-8 receptor-binding site, did not impact the affinity to heparin. 
Affinity was decreased with truncation at the C terminus, and no binding was observed when the 
C-terminal alpha-helix was eliminated. When they induced neutrophils with IL-8 and heparan 
sulfate, neutrophil chemotaxis in vitro was enhanced up to 4-fold, whereas IL-8 alone did not 
enhance the chemotaxis of neutrophils. Therefore, these data emphasized that heparan sulfate 
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plays important functions in enhancing IL-8 dependent migration of neutrophils, as well as 
preventing IL-8 from lytic enzyme released from the migrating cells (164). 
1.7.4. Interleukin 11 (IL-11) 
IL-11, a member of the gp130 receptor family of cytokines, plays essential functions in 
T-cell-dependent development of immunoglobulin-producing B cells and synergizes with IL-3 in 
supporting murine megakaryocyte colony formation (165). Walton and colleagues investigated 
the cooperative activity between IL-11 and heparin to induce STAT3 activation (166). Their 
results revealed that heparin enhances both IL-11–induced STAT3-DNA complex formation and 
transactivation with unchanged level of STAT3 tyrosine or serine phosphorylation. Furthermore, 
heparin was also found to enhance IL-11’s ability to induce the expression of both receptor 
activator of nuclear factor–B ligand (RANKL) and glycoprotein (gp) 130. 
Rajgopal and colleagues examined the effect of serine kinase inhibitors on the co-
operative activity between heparin and IL-11 (167). They found that heparin synergistically 
enhanced IL-11 signaling through up-regulation of the mitogen-activated protein kinase (MAPK) 
pathway. Heparin was found to increase IL-11-induced Erk1/2 activation in a time-and dose-
dependent manner. These findings suggested that heparin enhanced IL-11-induced STAT3 
activation and involved up-regulation of the MAPK pathway. 
1.7.5.  Interleukin 12 (IL-12) 
IL-12 was shown to strongly bind to immobilized heparin-BSA complex (168). This 
binding affinity was determined greater than interactions between heparin and two well-known 
heparin-binding proteins, anti-thrombin III and FGF (168). Furthermore, key residues of the 
interaction between heparin and IL-12 were identified as N-sulfated glucoamine-2-O-sulfated 
iduronate disaccharides (168). These results showed for the first time that IL-12 is a heparin-
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binding cytokine. A follow up study from the same group used truncated IL-12 molecules to 
narrow down the heparin binding domain to the D3 region on p40 (169). 
The biological consequences of heparin-IL-12 binding was investigated in several studies 
by our group. (169-171). Jayanthi and colleagues developed a novel method to purify 
recombinant IL-12 protein (170). They showed a robust heparin-affinity based purification of 
recombinant IL-12 from the supernatants collected from hIL-12 transduced HEK293 cells. 
Putative heparin binding sites on hIL-12 were predicted on p40 subunit by using an in silico 
analysis. In a follow up study, it was shown that that heparin binds to IL-12 with low micromolar 
affinity and enhances the biological activity of IL-12 by up to 6-fold (171). Heparin potentially 
induced dimerization of hIL-12 and modestly protected hIL-12 from proteolytic degradation. 
Using a flow cytometry-based binding assay, the amount of hIL-12 bound to cell surfaces was 
increased in the presence of heparin. Recently, Garnier and colleagues characterized the 
interaction between heparin and IL-12 using several types of chemically modified heparins 
(169). Using endoprotease LysC as a proteolytic enzyme, they showed that heparin only 
protected the p40 subunit from proteolytic degradation in comparison with p35 subunit. This 
further suggests that the p40 subunit is the location of the heparin binding site. The endoprotease 
LysC was employed in this study because it cleaves adjacent to lysine residues, which due to 
their strongly basic side chains and are along with arginine, key residues in heparin binding sites 
(169). 
1.8. Significance of the dissertation 
IL-12 serves as a key link between innate and adaptive immunity based on its production 
by antigen presenting cells and its ability to activate natural killer (NK) cells and T lymphocytes 
(172). IL-12 is a potent cytokine that significantly enhances cell-mediated immune responses. 
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Due to this potent activity, IL-12 has been used in the clinic for the treatment of intracellular 
pathogens (173), and HIV infection (174). Our group and others are exploring the use of IL-12 
for cancer immunotherapy (55, 60, 61, 69, 116). 
Heparin, a negative charge glycosaminoglycan (GAG), is known to modulate the 
function of numerous cytokines, generally having a neutral or inhibitory effect (136, 142, 146, 
152). Using in silico analysis, we found heparin-binding domains located on the p40 subunit of 
IL-12. These sites were exploited to purify recombinant IL-12 in a single-step purification 
procedure (170).  
Prior to this dissertation research, the effect of heparin on the bioactivity of IL-12 had not 
been studied. After demonstrating, for the first time, that heparin binds to IL-12 with low 
micromolar affinity and increases IL-12 bioactivity by more than 6-fold (Chapter 2) (171), our 
research focused on understanding the mechanisms by which heparin influences IL-12 
bioactivity. In Chapter 3, we demonstrated the characteristics of heparin that were necessary for 
enhanced IL-12 activity. Based on these required characteristics, we developed the first working 
model of stabilization which hypothesized that heparin molecules of sufficient length are able to 
span heparin binding domains on different subunits of IL-12 and its receptor. Binding to multiple 
subunits would serve to enhance or stabilize the IL-12/IL-12R complex leading to enhanced 
signaling. Additional research, found in Appendix 1, demonstrated for the first time, the ability 
of heparin to recover IL-12 signaling in cells deficient in the IL-12R1 receptor subunit. 
Although the mechanism of IL-12 recovery could not be determined. 
Taken together, the findings presented in this dissertation reveal a novel 
immunomodulatory function of heparin on one of the most important cytokines in human 
immunity. Completed studies describe the unique structure-function relationship of heparin and 
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IL-12 and improve our understanding of IL-12 immunobiology. In addition to these 
contributions to basic immunology, in the future, data in this dissertation may be exploited in the 
development of novel heparin-based delivery systems or IL-12-based immunotherapies. 
Furthermore, this research has significant implications in other IL-12 family cytokines which 
share similar subunits and subunit receptors.  
1.9. Hypothesis and Specific Aims 
Given that heparin modulates the activities of numerous cytokines, we hypothesized that 
the interaction of heparin and IL-12 plays a role in modulating biological functions of IL-12. To 
address this hypothesis as well as to study the mechanisms of heparin-induced IL-12 modulation, 
we proposed three specific aims: [1] assess heparin-induced modulation of IL-12 bioactivity, [2] 
explore the molecular mechanism(s) underlying heparin-induced modulation of IL-12 
bioactivity, and [3] investigate the effect of heparin on IL-12 bioactivity in IL-12R1 deficient 
cells. 
In the first specific aim, we quantified the affinity of the heparin-IL-12 interaction and its 
biological effects in multiple cell types. Heparin was compared to other glycosaminoglycans to 
determine if binding as well as any immunomodulatory effects on IL-12 were specific to heparin. 
We also investigated biophysical and biochemical parameters to determine if heparin altered IL-
12 conformation or susceptibility to proteolytic digestion.  
In the second aim, we extended our study to examine characteristics of heparin that play 
essential roles in modulating hIL-12 bioactivity. Ultimately, we sought to develop a working 
model that describes how heparin interacts with IL-12 and its receptor subunit to enhance 
signaling.  
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In the third aim, because preliminary data demonstrated that heparin was able to recover 
the bioactivity of IL-12 in cells expressing non-functional IL-12 receptors, we sought to 
elucidate the mechanisms underlying this recovery. Experiments were performed in 2 cell types 
that lacked normal IL-12R1 expression including IL-12R1 deficient PBMCs from MSMD 
patients and IL-12R1 mutant NK-92MI cells. 
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CHAPTER 2: MODULATION OF INTERLEUKIN-12 ACTIVITY IN THE PRESENCE 
OF HEPARIN * 
2.1. Introduction 
Polyanionic glycosaminoglycans (GAGs) have been shown to bind numerous growth 
factors and cytokines (1-5). The physiological significance of this binding is two-fold. First, 
GAGs can serve as co-receptors on cell surfaces to maintain high, local concentrations of 
cytokines (6-10).  Second, GAGs can regulate bioactivities of growth factors and cytokines 
through multiple mechanisms including dimerization and protection from proteolytic degradation 
(11-14).  The two most heavily N-sulfated GAGs, heparin and heparan sulfate (HS), are known 
to interact with more than 400 proteins involved in various biological processes (10).  In its most 
obvious role, heparin binds to antithrombin and increases its anticoagulant activity.  Heparin 
binding is also an essential prerequisite for basic fibroblast growth factor (bFGF) dimerization 
and engagement with its high affinity receptor for angiogenesis, wound healing, stem cell 
differentiation, etc. 
Beyond antithrombin and bFGF, the binding of sulfated GAGs plays a significant role in 
the biology of numerous other pleiotropic cytokines and growth factors (15-18).  For example, 
binding of GM-CSF to sulfated GAGs in the extracellular matrix produced by stromal cells is 
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critical for maintaining high local concentrations in the bone marrow microenvironment (19) and 
increasing GM-CSF-induced myeloid cell proliferation (20).  Additionally, heparin binding 
decreases IFN- clearance (21), interferes with cellular binding (22) and inhibits IFN--induced 
upregulation of class II MHC and adhesion molecules on the surfaces of vascular endothelial 
cells (15, 23). 
GAG-interleukin interactions have been explored, albeit to a significantly lesser extent. 
Interleukins mediate signaling primarily between leukocytes.  Given that leukocytes are highly 
mobile populations of cells, the need for compartmentalization of interleukins through GAG 
binding is not as obvious.  Nevertheless, heparin and HS have been shown to bind to many 
interleukins with mixed effects on their bioactivities.  
Heparin binds to human but not murine IL-2 (24, 25), however, heparin binding has no 
effect on hIL-2 bioactivity as measured by proliferation of CTLL-2 cells (25).  The effect of 
heparin/HS binding on IL-3 bioactivity is concentration-dependent with IL-3-induced 
proliferation of myeloid cells increasing at low heparin concentrations and decreasing at high 
heparin concentrations (20).  HS binds to and inhibits IL-4-based suppression of 
lipopolysaccharide-stimulated monocytes (26).  Yet, HS enhances the proliferative activity of IL-
5 in specialized Baf-IL-5 cells (27).  Heparin/HS has no impact on IL-6-stimulated proliferation 
of Ba/F3 cells (28).  Heparin complexation protects IL-7 from proteolytic degradation, however, 
heparin binding inhibits the growth of IL-7 dependent pre-B cells (29).  HS augments IL-8-
induced neutrophil chemotaxis and Ca2+ responses (30) while heparin facilitates similar IL-8-
induced Ca2+ responses but either inhibited, or had no impact on, neutrophil chemotaxis (30, 31). 
Lastly, heparin and HS both inhibit IL-10-induced upregulation of CD16 and CD64 on 
monocytes/macrophages (13).  In general, while the effects of heparin/HS on interleukin 
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bioactivity are mixed, interleukin binding to highly sulfated GAGs appears to be more inhibitory 
than augmentative.   
IL-12 has been shown previously to be a heparin-binding protein (32, 33).  Our recent in 
silico analysis found two heparin-binding domains located on the p40 subunit of IL-12 (33).  
These sites were exploited in the single-step purification of tagless IL-12, while the affinity of 
heparin for IL-12 was well characterized via isothermal calorimetry (ITC) (33).   
In this study, the ability of heparin/HS to modulate IL-12 bioactivity is described for the 
first time. In an effort to determine the mechanism(s) by which heparin influences IL-12 
bioactivity, comprehensive biophysical and cell-based studies were performed. Specifically, we 
assessed the ability of heparin to: [1] stabilize IL-12 conformation; [2] protect IL-12 from 
proteolytic degradation; [3] induce oligomerization of IL-12; and [4] enhance IL-12 binding to 
cell surfaces and IL-12 receptors. Results of this study are important in that they contribute 
significantly to our understanding of the immunobiology of IL-12 and potentially other IL-12 
family cytokines which have been recently suggested as having more influence on shaping 
immunity than any other cytokine family (34). 
2.2. Materials and Methods 
2.2.1. IL-12 bioactivity assays 
Recombinant hIL-12 was purified from hIL-12-expressing HEK-293 cells as described 
previously (33).  Low molecular weight heparin, HS, hyaluronic acid, chondroitin sulfate and 
dextran were purchased from Sigma-Aldrich. 
The IL-2-independent, IL-12-responsive human natural killer cell line, NK-92MI (CRL-
2408TM; ATCC), was cultured in complete media consisting of Alpha MEM supplemented with 
12% fetal bovine serum, 12% horse serum, 1% penicillin/streptomycin, 0.2 mM inositol, 0.02 
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mM folic acid, and 0.1 mM 2-mercaptoethanol. Cell density was maintained between 1x105 and 
1x106 viable cells/mL using a 1:3 split ratio. Peripheral blood mononuclear cells (PBMCs) were 
isolated from whole blood on a density gradient (Lympholyte H; Cedarlane Labs). Whole blood 
was either collected from healthy donors, under informed consent, as approved by the 
Institutional Review Board at the University of Arkansas, or purchased, de-identified, from the 
New York Blood Center. All experiments were performed in accordance with relevant guidelines 
and regulations at the University of Arkansas, the University of North Carolina and North 
Carolina State University. 
IFN-γ secretion from NK-92MI cells and PBMCs was used as an indicator of hIL-12 
bioactivity.  NK-92MI cells and PBMCs were seeded in a 96-well plate at 20,000 and 100,000 
cells/well, respectively. hIL-12 was added to achieve final concentrations from 0.04 to 5 ng/ml.  
Heparin, HS, hyaluronic acid, chondroitin sulfate or dextran was added to a final concentration 
of 10 µg/ml. Cells in hIL-12 alone or culture media alone served as controls. After 24-48 hours, 
hIL-12-dependent secretion of IFN-γ into the supernatant of the culture was quantified via 
enzyme-linked immunosorbent assay (ELISA) (88-7317; eBiosciences). For PBMC subset 
analysis, stimulated cells were analyzed for intracellular IFN- expression on a BD Celesta flow 
cytometer (BD Biosciences). 
HEK-BlueTM IL-12 cells (Invivogen) express a STAT4-inducible secreted embryonic 
alkaline phosphatase (SEAP) reporter gene that is triggered upon binding of IL-12 to IL-12R. 
HEK-BlueTM IL-12 cells were seeded onto a 96 well plate at 50,000 cells/well and exposed to 
media containing 0.04 to 20 ng/ml hIL-12 with or without 10 µg/ml heparin. After 12 hours, 
SEAP concentrations in supernatants were detected through the addition of Quanti-BlueTM 
(Invivogen) and quantified via absorbance readings at 650 nm. 
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2.2.2. IL-12-GAG binding studies 
Binding affinities between hIL-12 and various GAGs were quantified by isothermal 
titration calorimetry on an iTC200 (MicroCal Inc.). Both hIL-12 and GAGs were prepared in 10 
mM sodium phosphate buffer with 100 mM sodium chloride at pH 7.2. All samples were 
subjected to high speed centrifugation to remove any suspended particulate material and 
degassed to remove dissolved air before titration. GAGs (2 mM) were titrated into hIL-12 (200 
µM) for a total of 30 injections.  Titrations were performed at physiological temperature (37oC).  
Titration curves were fit to the one-set of sites binding model using OriginTM v7.0 software to 
derive binding constants.  
2.2.3. Proteolytic digestion assays 
To evaluate hIL-12 degradation in spent media, NK-92MI cells were cultured in media 
without serum for 3 days at a starting cell density of 1x106 cells/ml.  Spent media were collected, 
centrifuged, 0.2 m-filtered and co-incubated with 500 pg/ml hIL-12 ± 10 g/ml heparin. Fresh 
cell culture media with 50 g/ml bovine serum albumin as a stabilizing protein was used as a 
negative control. Fresh cell culture media with 0.125% trypsin was used as a positive control. 
Samples from each treatment were collected at 0, 24, 48 and 72 hours. Full length hIL-12p70 
concentrations were quantified via ELISA (88-7126; eBiosciences).  
To evaluate hIL-12 degradation by known proteases, trypsin, chymotrypsin, thermolysin, 
thrombin and protease inhibitor cocktail tablets were purchased from Sigma-Aldrich. A protease 
cocktail was prepared by mixing trypsin, chymotrypsin, thrombin and thermolysin in PBS. hIL-
12 (1 g/ml) ± heparin (10 g/ml) was added to the cocktail at protein to protease molar ratio of 
10:1. PBS with 0.1% w/v bovine serum albumin as a stabilizing protein was used as a negative 
control. The mixture was incubated at room temperature and samples were collected at 0, 1, 2, 5, 
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10, 15, 20 and 30 min. Full length hIL-12p70 concentrations were quantified via ELISA (88-
7126; eBiosciences). 
2.2.4. Size exclusion chromatography 
Oligomerization of hIL-12 in the presence of heparin was observed on a Sephacryl S-200 
size exclusion chromatography column connected to an AKTA fast protein liquid 
chromatography system.  All samples were resolved at room temperature at a flow rate of 1 
mL/min in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl.  The apparent 
molecular mass of the hIL-12 samples was determined against a standard curve constructed 
under similar conditions using common protein standards – β-amylase (200 kDa), alcohol 
dehyrogenase (150 kDa), conalbumin (75 kDa), ovalbumin (45 kDa), carbonic anhydrase (29 
kDa) and RNaseA (13.7 kDa). 
2.2.5. Circular Dichroism 
The secondary structure of hIL-12, in the presence and absence of heparin, was 
monitored by far-UV circular dichroism (CD) using a Jasco-710 spectropolarimeter.  Samples 
contained 100 µM hIL-12 in 10 mM sodium phosphate buffer (pH 7.2) with 100 mM sodium 
chloride.  A total of 15 scans were acquired at 25oC with a scan speed of 50 nm/minute.  Data for 
hIL-12 with heparin at a 1:5 molar ratio were collected under the same conditions.  Appropriate 
blank titrations were performed to eliminate background noise.  Processed data was expressed in 
molar ellipticity (deg. cm2. dmol-1). 
2.2.6. Differential Scanning Calorimetry 
Thermal denaturation of hIL-12 (100 µM), in the absence and presence of heparin, was 
performed on a NANO DSC III differential scanning calorimeter (TA Instruments) with a 
ramping temperature of 1oC/min spanning from 10oC to 90oC in 10 mM sodium phosphate buffer 
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(pH 7.2) containing 100 mM sodium chloride.  Thermodynamic values were calculated using 
OriginTM v7.0 software 
2.2.7. Equilibrium unfolding and ANS binding 
Guanidine hydrochloride-induced unfolding was performed on 10 µM hIL-12 in the 
presence and absence of heparin. The equilibrium unfolding data was plotted to derive the 
melting concentration (Cm) and ΔG (H2O). The surface accessible non-polar surfaces in hIL-12, 
in the presence and absence of heparin, was monitored by 8-anilinonaphthalene-1-sulfonic acid 
(ANS) fluorescence. All fluorescence experiments were performed at 25°C on a Hitachi F2500 
spectrofluorimeter. The excitation wavelength was set to 280 nm and bandwidths for excitation 
and emission were set to 2.5 and 10 nm, respectively. A stock solution of 20 mM ANS solution 
was used for titration into 10 µM hIL12 in 10 mM sodium phosphate buffer (pH 7.2) containing 
100 mM sodium chloride. Samples were excited at 380 nm and emission spectra were monitored 
between 450 to 600 nm with a peak observed at 500 nm. Data from the ANS binding assay were 
overlaid to identify differences in surface hydrophobicity. 
2.2.8. Small-angle X-ray Scattering (SAXS) Analysis 
SAXS data of hIL-12, in the absence and presence of heparin, was acquired at the Cornell 
High Energy Synchrotron Source (CHESS) beamline G1 source.  Inline size exclusion 
chromatography (SEC) was used to minimize polydispersity.  hIL-12 (150 µM), with and 
without low molecular weight heparin (in ten-fold excess) was loaded onto a Sephacryl-S 300 
column attached to AKTA explorer (GE Healthcare).  Eluted protein sample entered the flow 
cell of the BioSAXS at CHESS and was subjected to X-ray beam exposure.  Beamline 
characteristics used for acquiring the data were as follows: energy = 9.968 keV (1.257 A); beam 
diameter = 250 µm x 250 µm; photon flux = 1.6 x 1011 photons/sec.  The detector used for this 
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experiment is a dual Pilatus 100K-S with a q-space range between 0.006 to 0.8 Å.  Data acquired 
was processed using BioXTAS RAW software for performing the buffer subtraction.  Buffer 
subtracted plots were analyzed using the ATSAS program (35) with a sequence of steps to obtain 
an average low resolution structure. 
2.2.9. Heparin binding and IL-12 bioactivity on IL-12R mutant and wild-type cells 
Both IL-12 receptor subunits, IL-12R1 and IL-12R2, were functionally deleted from 
NK-92MI cells via CRISPR/Cas9 genome editing (see 2.2.10 for details). The resulting mutants 
are denoted as IL12R1mut/IL12R2mut NK-92MI cells. For analysis of cell surface binding, 
wild-type NK-92MI cells, IL12R1mut/IL12R2mut NK-92MI cells, PBMCs and HEK-293 cells 
(CRL-1573; ATCC) were incubated at 4°C, to inhibit cellular uptake, with Alexa Fluor 647 
(ThermoScientific)-labeled hIL-12 (AF647-IL12) (10 ng/ml), in the presence and absence of 10 
g/ml heparin.  Cells in culture media alone served as controls.  After one hour, cells were 
analyzed on a BD FACSCantoII or a BD Celesta (BD Biosciences).  
To assess the effect of IL12R deletion on heparin binding, parental NK-92MI and 
IL12R1mut /IL12R2mut cells were exposed to 10 g/ml heparin, labeled with Cyanine5 
(heparin-Cy5) (Nanocs), for 1 hour at 4 °C.  Cells in culture media alone served as controls.  
After one hour, cells were washed once with cold PBS and analyzed on a BD FACSCantoII.  
To assess the effect of heparin on hIL-12 bioactivity in IL12R mutant cells, parental NK-
92MI and IL12R1mut/IL12R2mut cells were cultured with 200 pg/ml hIL-12 ± 10 g/ml heparin 
for 24 hours.  IFN- production was quantified by ELISA as described above. 
2.2.10. CRISPR/Cas9-mediated deletion of IL12Rβ1 and IL12Rβ2  
Two 20-bp guide sequences, (5’-GGAGCACTCGTAACGATCAC-3’) and (5’- 
CAGGATTAACTTGTTACGTC-3’), targeting DNA within exon 305 – 419 of IL12Rβ1 and exon 
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717 – 1004 of IL12Rβ2, respectively, were selected from “the CRISPR design tool” provided by 
the Zhang lab at MIT (http://crispr.mit.edu/). Guide sequences were cloned into separate pCas-
GuideEF1a-GFP plasmids provided by Origene. Plasmids were amplified by E. coli and then 
purified using QIAGEN Plasmid Maxi Kit. 
NK-92MI cells (2x106 cells) were re-suspended in 100 μl of the electroporation buffer 
(Harvard Apparatus, Holliston, MA) and added to an electroporation cuvette. Plasmid (10 μg) was 
added to the electroporation cuvette and mixed well by pipetting. The cell suspension was 
electroporated with 250 volts, 25 ohms, and 750 μF in a 2 mm cuvette using the electroporation 
system ECM630 (Harvard Apparatus, Holliston, MA). Electroporated cells were then transferred 
to pre-warmed 1 ml culture media in a well of 6-well plate. These cells were cultured at 37oC for 
72 hours. 
NK-92MI transfected cells were harvested by centrifugation and diluted to a 
concentration of 2x106 cells/ml in PBS. Then, the cells were filtered through a 50 μm filter into a 
FACS tube. The transfected cells were sorted using FACS Aria III system (BD Biosciences). 
Only the top 5% of GFP-positive cells were collected to ensure high transfection levels of 
CRISPR/Cas9 complexes. 
To create a double mutant IL12Rβ1mut/IL12Rβ2mut NK-92MI cell line, IL12Rβ2 was first 
functionally deleted. An IL-12Rβ2mut clone was selected and propagated for one month to allow 
transient GFP expression to subside. IL12Rβ1 was subsequently functionally deleted using the 
transfection method described above. Cells were once again sorted and cloned. Functional 
deletion of IL12Rβ1 and IL12Rβ2 was verified by loss of IL-12 responsiveness (Fig. 2.5). 
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2.2.11. Analysis of Intracellular IFN-γ expression in PBMC subsets 
One million freshly isolated human PBMCs were stimulated with IL-12 alone (200 
pg/ml) or IL-12 plus heparin (10 µg/ml) for 12 hours in a 96 well plate. Monensin (554724; BD 
Biosciences) was added for the last 10 hours of stimulation to block intracellular transport. After 
12 hours of stimulation, cells were rinsed and stained with viability markers (Fixable Viability 
Stain 510; BD Biosciences) followed by blocking Fcγ receptors (564220; BD Biosciences) and 
staining for the following cell surface markers: CD3 (clone: UCHT1), CD19 (clone: SJ25C1), 
CD4 (clone: RPA-T4), CD8 (clone: RPA-T8), CD56 (clone: B159) and CD45 (clone: HI30). 
After surface staining, cells were fixed and permeabilized (554715; BD Biosciences) prior to 
staining for IFN-γ (clone: B27). Twenty thousand live PBMCs were acquired on a BD 
FACSCelesta (BD Biosciences) and analyzed using FlowJo v10 software (FlowJo LLC, 
Ashland, OR). 
2.2.12. IL12R expression in mutant NK-92MI via flow cytometry and western blot. 
For analysis of IL12R expression via flow cytometry, IL12Rβ1mut/IL12Rβ2mut and 
wildtype NK-92MI cells were stained with 1 μg/106 cells of APC-conjugated anti-IL12Rβ1 
(FAB839A; R&D Systems), APC-conjugated anti-IL12Rβ2 (FAB1959A; R&D Systems) or 
APC-conjugated mouse IgG1, k isotype control (550854; BD Biosciences). Cells were rinsed 
twice in cold PBS and read on a BD FACSCelesta. Data were analyzed using FlowJo v10 
software (FlowJo LLC, Ashland, OR). For qualitative assessment of IL12R expression via 
western blot, IL12Rβ1mut/IL12Rβ2mut and wild-type NK-92MI cells as well as HEK-293 cells 
(negative control) were lysed using RIPA lysis buffer with a protease and phosphatase inhibitor 
cocktail (78440; ThermoFisher). Homogenates were incubated for 5 minutes and then 
centrifuged at 13,000 × g for 10 minutes at 4 °C. Cell lysates were collected by withdrawing the 
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supernatant without disturbing the pellet. Protein concentration was estimated via bicinchoninic 
acid assay (BCA) (23250; Pierce). 50 µg/lane of protein was separated on 12% SDS-PAGE 
under reduced condition. The proteins were transferred onto a polyvinylidene difluoride (PVDF) 
membrane and blocked with Odyssey Blocking Buffer (927-50000; LI-COR Biosciences) at 
room temperature for 2 h. The membranes were then probed overnight with rabbit anti-IL12Rβ1 
antibody (ab96517; Abcam), mouse anti-IL12Rβ2 (MAB19591; R&D Systems) and mouse anti-
beta-actin (ab8226; Abcam) in Odyssey Blocking Buffer. Beta-actin was used as the gel loading 
control. Primary antibodies were used at a dilution of 1:5000. Secondary antibodies, goat anti-
rabbit IgG H&L-alkaline phosphatase (ab97048; Abcam) and goat anti-mouse IgG H&L - 
alkaline phosphatase (ab97020; Abcam) were used at a dilution of 1:5000. After blotting, protein 
bands were developed with NBT/BCIP substrate solution (34042; ThermoFisher). Qualitative 
images of blots were taken with an 8.0-megapixel digital camera. 
2.2.13.  Statistical analysis 
All experiments were carried out in triplicate or quadruplicate. Where appropriate, data 
are presented as mean ± standard deviation. Where indicated, analysis of variance (ANOVA) or 
Student’s t-test were performed using Prism 7 software (GraphPad Software, Inc, La Jolla, CA). 
Statistical significance was accepted at the p ≤ 0.05 level. 
2.2.14. Data availability statement 
All data and relevant materials are available from the corresponding author upon 
reasonable request. 
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2.3. Results 
2.3.1. Effect of heparin and other GAGs on hIL-12 bioactivity 
IFN-γ production from NK-92MI cells exposed to hIL-12 in the presence and absence of 
heparin was used as a measure of hIL-12 bioactivity.  NK-92MI cells produced low levels of 
IFN-γ (47.3±7.0 pg/ml) in the absence of hIL-12 (Fig. 2.1A).  Upon exposure to 0.04 to 5 ng/ml 
hIL-12, IFN-γ concentrations increased steadily from 48±7 to 1523±178 pg/ml.  Overall, the 
addition of heparin significantly augmented hIL-12-induced IFN- production by 55 to 661% 
(p<0.05 vs. hIL-12 alone via ANOVA).  Treatment of cells with heparin alone (0 pg/ml hIL-12) 
had no effect on IFN-γ production (p>0.05 vs. untreated controls via t-test). 
To determine if the order of heparin addition influenced hIL-12 bioactivity, heparin was 
added to culture medium 30 minutes before hIL-12, at the same time as hIL-12 or 30 minutes 
after hIL-12.  The order of heparin addition was found to have no effect (p>0.05 for all 
comparisons within each hIL-12 concentration via two-way ANOVA) (Fig. 2.1B). 
The effect(s) of other common GAGs, including HS, hyaluronic acid, and chondroitin 
sulfate, on hIL-12 bioactivity were also examined.  Similar to heparin, HS enhanced hIL-12-
mediated production of IFN-γ by about 2.5 times (Fig. 2.1C).  Conversely, chondroitin sulfate, 
hyaluronic acid and dextran, as a non-GAG control polysaccharide, had no discernable effect on 
hIL-12 bioactivity. 
To determine if the heparin-induced increase in hIL-12 bioactivity was a widespread 
phenomenon, similar experiments were performed in human PBMCs and HEK-BlueTM IL-12 
sensing cells.  Indeed, heparin significantly enhanced IL-12 bioactivity on both human PBMCs 
(Fig. 2.1D) and HEK-BlueTM IL-12 cells (Fig. 2.1E). In PBMCs, the effect was most pronounced 
at 200 ng/ml hIL-12 where IFN- production was increased by more than 3-fold in the presence 
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of heparin. The enhancing properties of heparin decreased at higher hIL-12 concentrations.  An 
analysis of intracellular IFN- expression by PBMC subsets via flow cytometry revealed that NK 
cells, and not CD4+ or CD8+ T cells, were primarily responsible for the observed increases in 
IFN- production (Supplementary Fig. S.2.1).   
2.3.2. Effect of heparin and other GAGs on hIL-12 binding 
ITC experiments were performed to compare the binding affinities between several 
GAGs and hIL-12.  The affinity of hIL-12 to heparin was found to be in the low micromolar 
range with an apparent Kd value of ~23 µM (Table 2.1).  HS also bound to hIL-12 in the low 
micromolar range (Kd ~9 µM).  However, no binding was observed between hIL-12 and the 
other GAGs or dextran examined. Representative isothermograms are shown in Supplementary 
Fig. S.2.2. 
The stoichiometry of binding, obtained from the fitting ITC data to a one-set of sites 
binding model, was approximately 1 for both HS/IL12 and heparin/IL-12 complexes (Table 2.1).  
This indicates a single binding site for heparin/HS on hIL-12.  Heparin/HS binding was 
accompanied by a large decrease in enthalpy (ΔH) and an increase in entropy (ΔS).  These 
changes indicate that the IL-12/heparin binding is facilitated by both hydrophobic and 
electrostatic interactions.   
2.3.3. Effect of heparin in preventing proteolytic degradation of hIL-12 
To determine if the heparin-dependent increase in hIL-12 bioactivity could be attributed 
to protection from proteolytic enzymes in cell culture media, the time-dependent degradation of 
hIL-12 in fresh and spent media, with and without heparin, was quantified.  Spent media were 
obtained from NK-92MI cells cultured at high density for 24 hours without serum 
supplementation.  After up to 72 hours of incubation, there was no appreciable degradation of 
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hIL-12 in spent media regardless of heparin addition (Fig. 2.2A).  In fact, concentrations of hIL-
12 in spent media or fresh media were indistinguishable.  The addition of strong proteolytic 
enzyme, trypsin, completely degraded hIL-12, apparently irrespective of heparin addition, within 
24 hours. In a follow up experiment, hIL-12 alone or hIL-12 with heparin, was cultured with a 
protease cocktail for up to 30 minutes (Fig. 2.2B). At this shorter time scale, it became apparent 
that heparin partially protects hIL-12 from strong proteolytic enzymes.  
2.3.4. Analysis of heparin-hIL-12 interactions 
Following up on the ITC binding studies, the nature of the interactions between heparin 
and hIL-12 was characterized by SEC and SAXS.  SEC revealed that hIL-12 migrated with an 
apparent molecular mass of 103.6 kDa (Table 2.2).  The difference between this apparent 
molecular mass from SEC and the experimental molecular mass of hIL-12 (65 kDa) obtained 
from our previous electrospray ionization-mass spectrometry analysis (33), could be attributed to 
the extensive glycosylation pattern that is found in this class of cytokines (36-40) and the 
extended, non-globular structure of hIL-12 (33, 41).  In the presence of heparin, hIL-12 showed 
an apparent molecular mass of ~172.9 kDa suggesting that binding of heparin likely induces 
dimerization of the protein. The marginal difference between the expected molecular mass and 
the observed molecular mass, calculated from the SEC experiment, can be attributed to the non-
globular nature of the IL12-heparin complex and also the minor uncertainties introduced due to 
data extrapolation on the standard molecular mass curve which did not include proteins of 
molecular mass greater than 180 kDa.   
SAXS analysis indicated that the average molecular mass of hIL-12, calculated from the 
radius of gyration, was approximately 70 kDa (Table 2.2).  This is in good agreement with the 
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predicted molecular mass of hIL-12 including glycosylation.  For heparin-hIL-12 complexes, the 
average molecular mass was approximately ~200 kDa which corroborates the SEC data.  
2.3.5. Effect of heparin on hIL-12 conformation and stability 
Far-UV CD measurements were performed to determine if heparin influenced the 
secondary structure of hIL-12.  In the absence of heparin, hIL-12 showed a strong negative 
ellipticity band at around 210 nm (Fig. 2.3A) and a shoulder around 222 nm indicating the 
presence of alpha-helix and beta-sheet secondary structures.  Incubating hIL-12 with heparin 
revealed only minor changes in the shape of the spectrum.  These results suggest that heparin 
does not induce discernable backbone conformational changes in IL-12. 
Intrinsic tryptophan fluorescence is a sensitive technique to monitor subtle tertiary 
structural changes induced by ligand binding.  An overlay of intrinsic fluorescence emission 
spectra in the absence and presence of heparin for hIL12 showed an identical emission maxima 
at 341 nm (Fig. 2.3B) suggesting there was no significant change in the microenvironment of 
tryptophan upon binding to heparin.  A marginal increase in the relative fluorescence intensity in 
the presence of heparin could be attributed to an increased rigidity in the tertiary structure of the 
protein with an enhanced hydrophobic content around the sites of tryptophan.  
Similar to thermal unfolding, proteins undergo denaturation in the presence of strong 
chaotropes such as, guanidinium salts or urea.  In this study, hIL-12 was subjected to 
guanidinium chloride-based equilibrium unfolding.  It was observed that hIL-12 is moderately 
stabilized in the presence of heparin as evidenced by an increase in the Cm value [concentration 
of the denaturant at which 50% of the protein population is in the denatured state(s)] from 2.0 M 
to 2.5 M (Fig. 2.3C-E).  
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ANS binding assay was used to monitor surface hydrophobicity and solvent accessibility 
of surface residues in hIL-12 in the absence and presence of heparin.  ANS is a hydrophobic 
fluorescent dye which binds to solvent-exposed non-polar surface of proteins. Emission spectrum 
of ANS upon binding to IL-12 shows an emission maximum at 500 nm.  The ANS 
concentration-dependent binding curve (Fig. 2.3F) shows a steady increase in the emission 
intensity at 500 nm (Fig. 2.3F) in the range of 0 – 200 μM and plateaus at higher concentrations.  
The ANS concentration-dependent binding curve in the presence of heparin shows a similar 
trend. However, the 500 nm emission intensity, in the presence of heparin, is marginally lower in 
the ANS concentration of 75 μM – 200 μM suggesting that the binding of heparin only causes a 
subtle conformational change in IL-12.  
To understand the effect of heparin on the thermal stability of hIL-12, protein unfolding 
was monitored using differential scanning calorimetry.  hIL-12 in the absence of heparin, 
showed a melting temperature (Tm) of ~ 65°C (Fig. 2.3G).  The unfolding process was 
irreversible as the cooling cycle did not show a sharp peak as observed during the heating cycle.  
In the presence of heparin, Tm increased marginally by only 1.2°C. 
2.3.6. Effect of heparin on cell surface binding of hIL-12 
Binding of AF647-hIL12 to NK-92MI cells, PBMCs and HEK cells in the presence and 
absence of heparin was assessed via flow cytometry.  The addition of AF647-hIL12 alone to NK-
92MI cells resulted in a significant shift in cell surface fluorescence compared to unstained 
controls (Fig. 2.4A).  When exogenous heparin was included, the mean fluorescence intensity 
due to AF647-hIL12 binding increased from 2,200 to 12,561.  
Recognizing that heparin could be facilitating non-specific binding to the cell surface, i.e. 
binding to moieties other than the IL-12 receptors, the experiment was repeated in NK-92MI 
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cells in which both IL-12 receptor subunits, IL12R1 and IL12R2, were functionally deleted 
via CRISPR-Cas9 gene editing. Indeed, disrupting the heterodimeric IL-12 receptor had no effect 
on the increase in AF647-hIL12 binding to the cell surface in the presence of heparin (Fig. 2.4B).  
Additionally, heparin binding, as visualized by heparin-Cy5, was not influenced by the IL12R 
deletion (Fig. 2.4C).  
Follow up western blot and flow cytometry assays, revealed that the 
IL12R1mut/IL12R2mut NK-92MI cells still expressed some portion of the IL12R subunits 
(Supplementary Fig. S.2.3). Therefore, an additional experiment was performed to measure hIL-
12 binding to HEK-293 cells which do not express IL12R and PBMCs which mostly do not 
express IL12R. Fig. 2.4D and 2.4E demonstrated that heparin modestly increases IL-12 binding 
to the surfaces of HEK-293 cells and PBMCs.  
Perhaps most interestingly, even though hIL-12 alone poorly bound in 
IL12R1mut/IL12R2mut NK-92MI cells, the addition of heparin almost completely restored hIL-
12 bioactivity (p< 0.0001 hIL-12 alone vs. hIL-12 plus heparin in mutant cells via two-tailed t 
test) (Fig. 2.5). In fact, IFN- production by the IL-12R mutant cells treated with hIL-12 and 
heparin was greater than 90% of the IFN- production by wild-type NK-92MI cells treated with 
hIL-12 plus heparin (p>0.05 hIL-12 plus heparin in mutant cells vs. hIL-12 plus heparin in wild-
type cells via two-tailed t test). 
2.4. Discussion 
Our previous study demonstrated that hIL-12 binds to heparin specifically and that 
heparin binding sites are primarily located on the p40 subunit of hIL-12 (33).  This study is the 
first to unambiguously demonstrate that heparin positively modulates the activity of hIL-12 (Fig. 
2.1).  Initial bioactivity studies were performed on a human NK cell line and subsequently 
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confirmed using human PBMCs and an IL-12-sensing HEK cell line.  Thus, the heparin-induced 
increase in hIL-12 activity appears to be widespread. A PBMC subset analysis revealed that NK 
cells, and not CD4+ nor CD8+ T cells, were responsible for the increase in IFN- production in 
response to stimulation with hIL-12 and heparin (Supplementary Fig. S.2.1).  
Binding and modulation of hIL-12 activity was restricted to heparin and HS, the two 
most N-sulfated GAGs.  Chondroitin sulfate and hyaluronic acid did not bind to hIL-12 nor did 
they have an effect on hIL-12 bioactivity.  The fact that dextran, chondroitin sulfate and 
hyaluronic acid did not influence hIL-12 bioactivity indicates that a high density of sulfation is 
critical for binding and modulating hIL-12. 
ITC binding analyses demonstrated that hIL-12 contains a distinct, accessible heparin 
binding pocket.  The low micromolar binding affinities for heparin and HS, together with 
moderate increases in entropy and decreases in enthalpy are indicative of a robust, specific 
electrostatic and non-polar interaction.  
SEC and SAXS data demonstrated that hIL-12 predominantly forms dimeric structures 
(Table 2.2).  This dimerization/oligomerization could help stabilize the IL-12/receptor complex. 
Similar observations have been made with other interleukins. The extracellular domain of IL-5R 
binds to a homodimeric form of IL-5 attaining a critical “wrench-like” structural conformation 
(42).  Likewise, IL-22 was shown to form dimers and tetramers in solution and organize into a 
V-shaped dimeric conformation binding to IL-22R1 receptor (43).  The effect of heparin on 
stabilizing the IL-12/receptor complex is the subject of ongoing studies.  
With respect to other mechanism(s) by which heparin modulates hIL-12 activity, we 
explored a number of possibilities based on the heparin literature. Heparin has been shown to 
protect proteins, such as bFGF, from the hydrolytic action of plasmin and other proteases present 
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in the extracellular milieu (44).  However, our data showed that hIL-12 was not significantly 
degraded by proteases or any other molecules that may be present in spent media (Fig. 2.2A). As 
expected, trypsin, used as a positive control, quickly and completely degraded hIL-12 equally in 
the presence and absence of heparin. Because trypsin digested all of the hIL-12 within the first 
time point, i.e. 24 hours, a subsequent experiment with a defined protease cocktail was 
performed over a shorter time frame. Within 30 minutes, heparin was found to reduce protease-
driven hIL-12 degradation by up to 14% (Fig. 2.2B). However, it should be noted that all hIL-12, 
regardless of heparin inclusion, is expected to be inactivated by the protease cocktail within a 
few hours. Thus, although heparin can somewhat protect hIL-12 from strong proteolytic 
degradation, this is not a plausible mechanism for the increased hIL-12 activity in vitro that we 
observed. 
Conformational analysis of hIL-12 in the presence and absence of heparin was performed 
as other heparin-binding proteins have been shown to be stabilized with heparin.  Biophysical 
characterization of heparin-hIL-12 binding via far-UV CD measurements, folding studies, ANS 
binding and thermal stability assays demonstrate that heparin causes a slight change in hIL-12 
conformation but no gross secondary or tertiary structural changes (Fig. 2.3).  There is also a 
minor increase in thermal stability. Taken together, conformational and stability changes are not 
so significant to suggest that they would lead to a major shift in hIL-12 bioactivity. 
The strongest evidence for the mechanism by which heparin enhances hIL-12 bioactivity 
points to heparin serving as a co-receptor for hIL-12.  Heparin clearly increases the concentration 
of hIL-12 at cell surfaces (Fig. 2.4).  The effect was more pronounced in cells expressing IL-
12R, e.g. mutant and wild-type NK-92MI. Nevertheless, a small increase in hIL-12 on the cell 
surface could also be found in cells expressing relatively little (PBMCs) or no IL-12R (HEK-
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293). That heparin binds to cell surfaces at high levels suggest that exogenous heparin is capable 
of maintaining a reservoir of IL-12 at the cell surface.  Heparin may also control the kinetics of 
association and dissociation of IL-12 to IL-12R1 and IL-12R2.  Ibrahami et al (45), studying 
the kinetics of the FGF signaling complex assembly, suggested that heparin regulates the cell 
proliferation activity due to FGF by switching FGFR between high and low affinity states.  
While heparin may bind to specifically IL-12R just as it does to FGFR, follow up studies showed 
that heparin binds equally to wild type and IL12R1mut/IL12R2mut cells (Fig. 2.4C).  Thus, it 
appears that heparin is binding at high levels to numerous proteins on the cell surface.  
Most surprisingly, heparin was shown to facilitate hIL-12 signaling in NK-92MI cells in 
which both IL-12R1 and IL-12R2 had been functionally deleted (Fig. 2.5). A follow up 
analysis of IL12R expression via flow cytometry and western blot indicate that forms of both IL-
12R1 and IL-12R2, although non-functional, were still expressed by the CRISPR/Cas9-
modified NK-92MI cells (Supplementary Fig. S.2.3). Thus, it is likely that during the Cas9 
dsDNA break, random insertion/deletion of nucleotides resulted in nonsynonomous mutations 
which allowed for expression of mutant IL12R subunits. Experiments to sequence the mutant 
IL12R subunits are planned.  
In the absence of heparin, hIL-12 likely has poor affinity to mutated IL-12R and thus 
loses its ability to signal. In the presence of heparin, the interaction of hIL-12 with IL12R1mut 
and IL12R2mut appears to be stabilized enough to recover hIL-12 signaling. Using a string tool 
algorithm developed by our group (46), we searched the amino acid sequences of IL12R1 and 
IL12R2 for putative heparin binding segments, e.g. XBXXBX, XBBXBX, BXBBXB, etc. 
where B is a basic residue and X is a non-basic residue. Results from this search indicated that 
the extracellular domain (ECD) of IL-12R1 contains 2 very prominent heparin binding 
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segments located at amino acids 293-298 and 454-459. The ECD of IL-12R2 contains 3 
potential heparin binding segments, amino acids 53-58, 273-278 and 353-358. Thus, heparin may 
simultaneously bind to and stabilize hIL-12 with one or both IL-12R subunits. Quantitation of 
heparin’s influence on the affinities of hIL-12 for wild-type and mutated IL-12R ECDs is the 
subject of ongoing research.  
 Data from these studies clearly demonstrate a physiological role for heparin in IL-12 
immunobiology.  The observed increase in hIL-12 activity in the presence of heparin is rare 
among interleukins, for which heparin-binding is typically more inhibitory than augmentative.  A 
potential evolutionary explanation for heparin binding is to compartmentalize IL-12 at specific 
sites.  IL-12, when administered systemically, is known to induce life-threatening adverse events 
(47).  Thus, heparin’s ability to localize IL-12, for example at a site of infection, while increasing 
its activity may provide a way to limit the systemic toxicity of this potent cytokine.  A similar 
compartmentalization phenomenon has been observed with other cytokines whose systemic 
dissemination is detrimental (48). Furthermore, the finding that heparin can recover IL-12 
signaling in cells with mutated IL-12R has significant implications for patients with atopic 
diseases driven by IL-12 family receptor point mutations (49, 50). These patients are susceptible 
to mycobacterial infections due to defects in the IL-12/IFN- axis. Strategies to use heparin to 
co-deliver IL-12 are now being developed by our group.  
Given the similarities among cytokines in the IL-12 family, our data also imply a role for 
heparin in modulating the activities of IL-23, IL-27 and IL-35.  IL-23, like IL-12, contains the 
heparin-binding p40 subunit, while IL-27 and IL-35 contain the Epstein-Barr virus induced gene 
3 (EBI3) subunit which is homologous to p40 (34, 51). Because the IL-12 family is central to 
 63 
human immunoregulation (34), the above studies should motivate further study of heparin as a 
surprisingly important immunomodulatory agent.  
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Table 2.1: Binding parameters of various GAGs interacting with IL-12 derived from ITC 
analysis 
 
 Kd (µM) Stoichiometry/ 
number of 
binding sites (n) 
ΔH 
[cal/mol] 
TΔS 
[cal/mol/oK] 
ΔG 
[cal/mol/oK] 
Heparin 23 ± 3.1 0.98 ± 0.02 -2526.2 4350.8 -1824.6 
Heparan sulfate (HS) 9 ± 1.2 1.01 ± 0.02 -1920.2 4350.8 -2430.6 
Chondroitin sulfate 
(CS) 
NB NB NB NB NB 
Hyaluronic Acid 
(HA) 
NB NB NB NB NB 
Dextran NB NB NB NB NB 
*NB – no binding observed 
   
 
Table 2.2: Comparison of MWapp of hIL-12 in the absence and presence of heparin using 
different methods 
 
 ESI-MS GPC Sephacryl-
S200 
SEC-SAXS 
- Heparin 65 kDa (33) ~100 kDa ~70 kDa 
+ Heparin Not performed ~170 kDa ~200 kDa 
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Figure 2.1. Effect of heparin and other GAGs on hIL-12 bioactivity. (A) hIFN-γ production 
by NK-92MI cells when incubated with media containing hIL-12 alone (white bars) or with 10 
µg/ml heparin (gray bars) was quantified using ELISA.  Heparin significantly enhanced hIL-12 
bioactivity (p<0.0001 vs. hIL-12 alone via two-way ANOVA) (B) hIFN-γ production by NK-
92MI cells when heparin (10 µg/ml) was added to NK-92MI cells at the same time as hIL-12 
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(gray bars), 30 mins prior to hIL-12 (checkered bars) or 30 mins after hIL-12 (horizontal). The 
order of heparin addition had no significant effect on hIL-12 activity (p>0.05 for all comparisons 
within each hIL-12 concentration via two-way ANOVA). (C) hIFN-γ production by NK-92MI 
cells cultured in media containing 200 ng/ml hIL-12 alone (-) or with heparin (Hep), heparin 
sulfate (HS), hyaluronic acid (HA), chondroitin sulfate (CS), or dextran (Dex) at 10 µg/ml was 
quantified using ELISA. Asterisks indicate a significant difference between indicated groups 
(*=p<0.01 and ***=p<0.001 via one-way ANOVA with Dunnett’s post hoc correction). (D) 
hIFN-γ production by PBMCs when incubated with media containing hIL-12 alone (white bars) 
or with 10 µg/ml heparin (gray bars) was quantified using ELISA. Heparin significantly 
enhanced hIL-12 bioactivity (p<0.0001 vs. hIL-12 alone via two-way ANOVA). (E) Alkaline 
phosphate activity by HEK-Blue™ IL-12 cells in response to incubation with media containing 
hIL-12 alone (white bars) or with 10 µg/ml heparin (gray bars) was determined in accordance 
with manufacturer’s instructions. Heparin significantly enhanced hIL-12 bioactivity (p<0.0001 
vs. hIL-12 alone via two-way ANOVA). All data are represented as mean ± standard deviation 
from triplicate samples. Experiments were performed in triplicate and repeated three times with 
similar results.  
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Figure 2.2. Effect of heparin on proteolytic degradation of hIL-12. (A) hIL-12 degradation 
when incubated with heparin (dashed lines) and without heparin (solid lines) in spent media 
(blue squares), fresh AMEM containing BSA (red circles) or fresh AMEM containing 0.125% 
trypsin (black triangles). Samples were collected at intervals of 0, 24, 48 and 72 hours and hIL-
12 concentrations were quantified via ELISA. Heparin did not affect hIL-12 degradation (p>0.05 
vs. hIL-12 alone via two-way ANOVA). (B) hIL-12 degradation when incubated with heparin 
(empty circles) and without heparin (filled circles) in protease cocktail containing trypsin, 
chymotrypsin, thrombin and thermolysin. Proteases were added to hIL-12 solution at a protein to 
protease molar ratio of 10:1. Samples were collected and neutralized with protease inhibitor 
cocktail at intervals of 0, 1, 2, 5, 10, 15, 20 and 30 min and hIL-12 concentrations were 
quantified via ELISA. Heparin significantly inhibited hIL-12 degradation by protease cocktails. 
Asterisks indicate a significant difference between groups at a particular time point (*=p<0.05 
vs. hIL-12 alone via two-tailed t-test). All data are represented as mean ± standard deviation 
from triplicate samples. Experiments were performed in triplicate and repeated three times with 
similar results. 
  
 68 
 
Figure 2.3. Effect of heparin on the conformation and stability of hIL12. (A) Overlay of the 
far-UV CD spectra (190 nm-250 nm) of hIL-12, in the absence (solid black) and presence (solid 
gray) of heparin. (B) Overlay of the steady-state fluorescence emission spectra on hIL-12 in the 
absence (empty circle) and presence (filled circle) of heparin. (C) Overlay of the equilibrium 
unfolding curves of IL-12, in the presence (filled circle) and absence (empty circle) of heparin. 
(D, E). A plot of the concentration of GdmHCl [M] versus ΔG (cal/mol) to determine the 
concentration (Cm) of the denaturant required for denaturation of 50% of the protein population, 
present in the native conformation. (F) Overlay of the ANS binding curves of hIL-12 in the 
absence (empty circle) and presence (filled circle) of heparin. (G) Overlay of the thermal 
denaturation curves of hIL12 in the absence (empty circle) and presence (filled circle) of heparin. 
Thermal denaturation was carried out by ramping the temperature at a rate of 1°C/min. Data 
obtained was plotted as heat capacity at constant pressure (Cp) versus temperature (°C) to obtain 
the Tm of hIL12. 
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Figure 2.4. Effect of heparin on hIL12 binding to cell surfaces. (A) NK-92MI cells, (B) IL-
12R1mut/IL-12R2mut NK-92MI cells, (D) HEK-293 cells or (E) PBMCs cultured with AF647-
IL12 alone (solid line) or AF647-IL12 plus 10 g/ml heparin (dashed line). Untreated cells 
(filled histogram) served as a negative control. (C) NK-92MI cells (solid line) and IL-
12R1mut/IL-12R2mut NK-92MI cells (dashed line) were cultured for at 4°C with heparin-Cy5. 
Untreated NK-92MI cells (filled histogram) served as a negative control. Each panel shows the 
relative amounts of AF647-IL12 or heparin-Cy5 binding to cells as assessed via flow cytometry. 
 70 
 
 
 
Figure 2.5. Heparin-induced recovery of hIL-12 activity. hIFN-γ production by parental NK-
92MI cells and IL-12R1mut/IL-12R2mut NK-92MI cells treated with 0 ng/ml hIL-12 (white 
bars) or 200 ng/ml hIL-12 (gray bars) in the presence and absence of 10 g/ml heparin was 
quantified via ELISA. The addition of heparin almost completely restored hIL-12 bioactivity in 
mutant cells (***p< 0.0001 hIL-12 alone vs. hIL-12 plus heparin in mutant cells via two-tailed t 
test) (p>0.05 hIL-12 plus heparin in mutant cells vs. hIL-12 plus heparin in wild-type cells via 
two-tailed t test), ns: not significant. All data are represented as mean ± standard deviation from 
triplicate samples. 
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Supplementary Figure S.2.1. Intracellular IFN-γ expression among PBMC subsets. Freshly 
isolated human PBMCs were stimulated with hIL-12 ± heparin and analyzed by flow cytometry. 
(A) Gating strategy for analysis of intracellular IFN-γ expression. IFN-γ positive populations 
were determined based on background production in cells that were not stimulated with IL-12. 
(B) PBMC subset analysis revealed that natural killer cells are the primary responders to hIL-
12+heparin stimulation. NK: natural killer cells; NKT: natural killer T-cells; PBMCs: peripheral 
blood mononuclear cells; IL-12: Interleukin-12; IFN-γ: Interferon-gamma. 
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Supplementary Figure S.2.2. Isothermograms for hIL-12 interactions with various GAGs. 
Isothermograms describe binding interactions between hIL-12 and (A) heparin, (B) heparin 
sulfate, (C) chondroitin sulfate, (D) hyaluronic acid, or (E) dextran. The upper panel of each 
isothermogram shows the raw data obtained for each of the 30 injections. The lower panels 
display the best fit data to one-set of sites binding model using OriginTM v7.0 software. 
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Supplementary Figure S.2.3. Analysis of IL12R expression in mutant and wild-type 
NK92MI cells. IL12Rβ1mut/IL12Rβ2mut and wild-type NK-91MI were stained with antibodies 
raised against IL-12Rβ1 and IL-12Rβ2 and analyzed via flow cytometry. (A) IL12Rβ1 
expression in wild-type NK-91MI cells (solid line) and IL12Rβ1mut/IL12Rβ2mut NK-92MI cells 
(dashed line). (B) IL12Rβ2 expression in wild-type NK-91MI cells (solid line) and 
IL12Rβ1mut/IL12Rβ2mut NK-92MI cells (dashed line). Isotype controls for wild-type NK-92MI 
cells (dark filled histogram) and IL12Rβ1mut/IL12Rβ2mut NK-92MI cells (light filled histogram) 
are displayed in each panel. Data are representative of three independent experiments. 
Expression of IL12Rβ1 (C) and IL12Rβ2 (D) was investigated by Western blotting. Lane 1: 
HEK-293 cells; Lanes 2-4: IL12Rβ1mut/IL12Rβ2mut NK-92MI cells; Lane 5: wild-type NK-
92MI; Lane 6: protein ladder. 
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CHAPTER 3: MOLECULAR MECHANISMS OF HEPARIN-INDUCED MODULATION 
OF HUMAN IL-12 BIOACTIVITY ** 
 
3.1. Introduction 
Sulfated GAGs, such as heparin and heparan sulfate, interact with and modulate the 
activities of numerous proteins (1). Although it is well known that heparin and heparan sulfate 
enhance the activities of growth factors, such as basic fibroblast growth factor (bFGF) (2-4), 
their effects on cytokines, particularly, interleukins are highly variable and often inhibitory. For 
example, heparin was shown to bind strongly to human IL-2 but has no effect on its bioactivity 
(5). IL-3-induced proliferation of FDCP-1 cells is inhibited at high heparin concentrations (6). 
The complex of heparin and IL-7 protects this cytokine from proteolytic degradation, however, 
the growth of IL-7 dependent pre-B cells is suppressed by heparin (7). Also, heparin prevents IL-
10-induced expression of CD16 and CD64 on monocytes/macrophages (8).  
IL-12, a central regulator of human immunity, has been shown by our group and others to 
be a heparin-binding protein (9-11). Our previous work identified two potential heparin-binding 
domains located on the p40 subunit of hIL-12 (10). These sites were exploited in the single-step 
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purification of tag-less hIL-12 (10). Recently, we demonstrated that heparin binds hIL-12 with 
low micromolar affinity and increases the activity of hIL-12 by several fold (12). Remarkably,  
heparin was found to recover hIL-12 signaling in a natural killer cell line, NK-92MI expressing 
mutant forms of IL-12Rβ1 and IL-12Rβ2 that were poorly active (12). 
In circulation, IL-12 induces profound systemic inflammation (13). It has been posited, 
therefore, that binding to sulfated GAGs present in extracellular matrix keeps IL-12 localized to 
a site of injury or infection and prevents its systemic dissemination. In addition to this 
localization effect, our recent studies indicated that sulfated GAGs, including heparin, increased 
IL-12 binding to cell surfaces (12). While this is one possible mechanism to increase IL-12 
signaling, a more complete picture of how heparin influences IL-12 function is needed.  
In the current study, because heparin is a polydisperse, heterogeneous polysaccharide, we 
began by exploring the effects of heparin’s biophysical characteristics on hIL-12 function in 
order to make inferences about heparin’s mechanisms of action. Specifically, because chain 
length, sulfation level and concentration have been shown to influence heparin’s ability to 
modulate growth factor activity (8, 14-17), we investigated the effects of these characteristics on 
hIL-12 binding and bioactivity. For robustness, bioactivity studies were performed in 4 different 
cell types: an NK cell line (NK-92MI), an IL-12 indicator cell line (HEK-BlueTM IL-12) as well 
as PBMCs and T cells from healthy donors. Additional bioactivity experiments were performed 
in a murine system to elucidate species-dependent differences. An analysis of cytokine 
production was performed to determine if heparin facilitates non-canonical hIL-12 signaling. 
Finally, data gathered were used to develop a proposed model for heparin-induced stabilization 
of hIL-12/hIL-12R which was visualized with molecular graphics software. 
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3.2. Materials and Methods 
3.2.1. Mice 
 Eight to ten week-old female C57BL/6J mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Animal use was in compliance with the Public Health Service 
(PHS) Policy on Humane Care and Use of Laboratory Animals. All experiments involving 
laboratory animals were approved by the Institutional Animal Care and Use Committee at North 
Carolina State University. 
3.2.2. Recombinant proteins and heparin compounds 
Recombinant hIL-12 was purified from hIL-12-expressing HEK293 cells as described 
previously (10). Recombinant mIL-12 was overexpressed by HEK293 cells stably transfected 
with optimized mIL-12p70 plasmid (AG250) (18). mIL-12-producing HEK293 cells were grown 
in serum-free media in a fiber cell bioreactor (FiberCell Systems, C2008). Recombinant mIL-12 
was purified via heparin sepharose chromatography as described previously (10). mIL-12 
cytokine production was quantified via ELISA (Thermo Fisher, BMS6004). Low molecular 
weight heparin (LMWH) and heparin oligosaccharides were purchased from Sigma-Aldrich and 
Iduron (Manchester, UK), respectively. Structurally homogeneous heparan sulfate (HS)-derived 
oligosaccharides were synthesized using a chemo-enzymatic approach. The purity analysis and 
structural characterization of the oligosaccharides were described previously (19, 20). 
3.2.3. Cell culture and isolation of human peripheral blood mononuclear cells 
(PBMCs) and T cells 
The IL-2-independent, IL-12-responsive human natural killer cell line, NK-92MI 
(ATCC; CRL-2408TM), was cultured in complete media consisting of Alpha MEM 
supplemented with 12% FBS, 12% horse serum, 100 U/mL penicillin/streptomycin, 0.2 mM 
inositol, 0.02 mM folic acid, and 0.1 mM 2-mercaptoethanol. The mIL-12 responsive T cell line, 
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2D6, was cultured in RPMI 1640 supplemented with 10% FBS, 100 U/mL 
penicillin/streptomycin, 2 mM L-glutamine and 250 pg/ml mIL-12.  HEK-BlueTM IL-12 cells 
(Invivogen, San Diego, CA) were maintained in DMEM supplemented with 2 mM L-glutamine, 
10% FBS, 100 U/mL penicillin/streptomycin and 100 g/mL normocin.  
Human PBMCs were isolated from leukopaks on a density gradient using Lympholyte H 
(Cedarlane Labs, CL5016). De-identified leukopaks from healthy donors were purchased from 
the New York Blood Center (New York City, NY). Human T cells were isolated from PBMCs 
by negative selection with magnetic beads (ThermoFisher, 11344D). PBMCs and T cells were 
cultured in RPMI 1640 medium supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-
glutamine, 10 mM HEPES, 100 U/mL penicillin/streptomycin. All experiments were performed 
in accordance with relevant guidelines and regulations at the University of North Carolina at 
Chapel Hill and North Carolina State University. 
3.2.4. IL-12 bioactivity assay and cytokine measurement 
IFN- secretion from NK-92MI cells, PBMCs and activated T cells was used as an 
indicator of hIL-12 bioactivity. T cells were activated by incubating 106 cells/ml with anti-
CD3/CD28 coated superparamagnetic beads (Thermo Fisher, 111.31D) in cultured media at a 
bead:cell ratio of 1:1 for 3 days. 
As described previously, cells were seeded in a 96-well plate at 20,000 cells/well (NK-
92MI) or 500,000 cells/well (PBMCs and T cells) (12). hIL-12 was added to achieve final 
concentrations from 0 to 1000 pg/ml. Heparin was added to a final concentration ranging from 0 
to 500 μg/ml. Cells in hIL-12 alone or culture media alone served as controls. After 24 h, hIL-
12-dependent secretion of IFN-γ into the supernatant of the culture was quantified via ELISA 
(Thermo Fisher, 88-7316-86). In other experiments, levels of human Th1/Th2/Th17 cytokines, 
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including IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A, in culture supernatants were 
determined via BD Cytometric Bead Array (CBA) (BD Biosciences, 560484) and analyzed using 
FACSDivaTM Software (BD Biosciences). 
In the murine system, 2D6 cells were starved of mIL-12 overnight before culturing 
(20,000 cells/well) with increasing doses of heparin (0 g/mL to 500 g/mL) and either mIL-12 
(200 pg/mL) or hIL-12 (200 pg/mL) in a 96-well plate. After 24 h, IL-12-induced proliferation 
was examined via CellTiter-Glo® 3D Cell Viability Assay (Promega, G9682). 
HEK-BlueTM IL-12 cells (Invivogen, San Diego, CA) express a STAT4-inducible 
secreted embryonic alkaline phosphatase (SEAP) reporter gene that is triggered upon binding of 
IL-12 to IL-12R. HEK-BlueTM IL-12 cells were seeded in a 96-well plate at 50,000 cells/well 
and cultured with 0 to 5 ng/ml hIL-12 and 0 to 500 μg/ml heparin. After 24 h, SEAP 
concentrations in supernatants were developed with Quanti-BlueTM (Invivogen, San Diego, CA) 
and quantified via absorbance readings at 650 nm on a Cytation5 microplate reader (Biotek, 
Winooski, VT). 
3.2.5. Intracellular flow cytometry 
 The following antibodies used for staining cell surface markers were obtained from BD 
Biosciences (San Diego, CA): anti-human CD3 FITC (clone: UCHT1), anti-human CD4 PerCP-
Cy5.5 (clone: RPA-T4), anti-human CD8 APC-R700 (clone: RPA-T8), anti-human CD56 PE-
CF594 or PerCP-Cy5.5 (clone: B159). Blocking of non-specific Fc receptor was performed by 
incubating cells with 25 g/mL human Fc block (BD Bioscience, 564220) in staining buffer 
(PBS supplemented with 0.2% BSA and 0.09% sodium azide). For intracellular staining of IFN-
, a protein transport inhibitor containing monensin (BD Biosciences, 554724) was added to the 
cells during induction. Cells were fixed in Fixation/Permeabilization Solutions (BD Biosciences, 
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554715) using the manufacturer’s recommended protocols. Anti-human IFN- BV421 (clone: 
B27) was used for intracellular IFN- staining. Data were acquired using a BD FACSCelesta 
flow cytometer (BD Biosciences) and analyzed using FlowJo software (Flow Jo LLC, Ashland, 
OR). IFN-+ cells were quantified in the gated CD3+CD4+ T cells, CD3+CD8+ T cells, and CD3-
CD56+ NK cells as illustrated in the gating strategies (Supplementary Figs. S.3.1 and S.3.2). 
3.2.6. Isothermal calorimetry 
 Isothermal Titration Calorimetry (ITC) experiments were performed on a iTC-200 
(Malvern Inc., UK) at 25 C. Both recombinant hIL-12 or mIL-12 (200 µM) and heparin 
oligosaccharides (2 mM) were dissolved in 10 mM phosphate buffer (pH 7.2) containing 150 
mM NaCl.  The molar ratios of hIL-12 or mIL-12 to heparin oligosaccharides were maintained at 
1:10. All solutions were degassed prior to titration.  Isothermal titrations were performed by 
injecting individual heparin oligosaccharides into hIL-12 or mIL-12 solutions in the reaction 
vessel. Isothermograms were obtained using 30 injections and were best-fit to a one-
site/multiple-site binding model using the OriginTM v7.0 software supplied by Microcal.  
Necessary blank corrections were performed to eliminate contributions originating from heats of 
dilution.  To account for inaccuracy associated with fitting of non-ideal/non-sigmoidal binding 
isotherms, the Kd values are reported as Kd(apparent).  
3.2.7. Microarray of HS-derived compounds 
A custom HS-microarray was fabricated as described previously (21). To prepare the array 
chip, 50 M HS oligosaccharides were dissolved in sodium phosphate buffer (pH 8.5, 50 mM).  
The solution was spatially arrayed onto NHS-activated slides (Nexterion® Slide H; SCHOTT, 
Jena, Germany) under ~50% relative humidity at 20oC. The robotic arrayer S11 (Scienion, Berlin, 
Germany) delivered 426 pL of HS oligosaccharide solution to 16 spots arranged in a 4 x 4 grid.  
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The array spots had an average diameter of about 80 m with a distance of 400 m between the 
centers of adjacent spots. The slides were incubated overnight in a saturated (NH4)2SO4 chamber 
(81% relative humidity). The slides were then washed with water to remove the unreacted 
oligosaccharides from the surface. The remaining N-hydroxysuccinimidyl groups were blocked by 
placing slides in a solution that contained 50 mM ethanolamine in PBST (137 mM NaCl, 13.2 mM 
Na2HPO4, 1.56 mM NaH2PO4, 2.68 mM KCl, 0.01% Tween 20) at 50°C for at least 1.5 h.  Slides 
were rinsed several times with deionized water, and the residual liquid was dried by centrifugation.  
The hybridization solution contained fluorescent-tagged hIL-12 (10 g/mL) and PBST 
(137mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 0.05% Tween 20), 20 mM Tris 
(pH 7.5) and 10% bovine serum albumin (BSA).  The solution was placed between the array slide 
and cover slip and incubated for 1 h at room temperature in a saturated (NH4)2SO4 chamber (81% 
relative humidity). The slide was then washed with 45 mL of PBST solution containing BSA (1%) 
and Tris (20 mM) for 5 min in a clean 50 mL conical tube. The wash process was repeated twice 
before analyzing the slide with an array scanner as described below.   
The array slides were scanned by a GenePix 4300 scanner (Molecular Dynamics). 
Scanning wavelength was 488 nm.  Resolution was set at 10 μm.  The array images were analyzed 
by GenePix Pro 7.2.29.002 software. Mean fluorescence intensities of array spots were calculated 
by Array Quality Control software. Some thresholds were listed as follows: median signal-to-
background, >10; mean of median background, < 500; median signal-to-noise, > 10; feature 
variation, 0.5; background variation, 0.5; features with saturated pixels, 0.1 %; not found features, 
7 %; bad features, < 7 %. 
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3.2.8. hIL-12/hIL-12R complex modeling 
Molecular modeling was performed using PyMOL molecular visualization software 
(Schrödinger, LLC) in conjunction with ClusPro protein-protein docking software and the 
Phyre2 web portal (22-27). The intensive modeling mode of the Phyre2 web portal was used to 
predict the structure of each IL-12 receptor subunit extracellular domain (ECD) based on 
primary structure and homogeneity to known protein structures. Next, hIL-12 protein (PDB: 
1F45) was used as an input into the ClusPro software together with each receptor subunit 
individually to calculate their likely placement (23, 24). From the top clusters predicted by the 
software, files with correct subunit interactions, i.e. hIL12Rβ1 with p40 and hIL12Rβ2 with p35, 
and orientation were chosen (28, 29). These two criteria alone eliminated all but two models per 
receptor subunit for a total of four clusters. The final two clusters were eliminated based on the 
non-phsyiological overlap of the receptor subunits when they were superimposed based on the 
hIL-12 protein in PyMOL.  
Heparin binding sites on each receptor subunit were predicted using ClusPro as well, 
using the heparin docking function. The top scoring segments for each of the subunits were 
selected and highlighted in the protein structure models. After each set of predictions was made, 
the location of each receptor in relation to the other was modeled by superimposing the hIL-12 
molecules onto each other using the ‘cealign’ command of the Alignment/Superposition plugin 
in the PyMOL software. After the alignment of each individual interaction based on the hIL-12 
molecule, no further modifications to the model were performed. 
Distances between heparin binding sites within the hIL-12/hIL-12R complex were 
determined using PyMol’s Measurement tool. For each measurement, residues within the heparin 
 87 
binding segments of interest that were closest to each other were used as endpoints. Within these 
residues, the carbon atom was chosen to approximate the distance between heparin binding sites. 
3.2.9. Statistical analysis 
All experiments were performed multiple times to ensure reproducibility. Two-tailed t 
test was used to compare the positive percentages of intracellular IFN- in response to hIL-12 
alone and hIL-12 plus heparin. An extra sum-of-squares F test was used to evaluate differences 
in the calculated EC50 value generated by hIL-12 alone and hIL-12 plus heparin. One-way 
ANOVA was used to discern differences in cytokine release from cells undergoing multiple 
treatments of a fixed concentration of hIL-12 and increasing concentrations of heparin (1 factor). 
Two-way ANOVA was used to distinguish differences of cytokine release from cells undergoing 
combination treatments of hIL-12 and heparin (2 factors). Tukey’s posttest was used after the 
ANOVA to compare individual treatment groups. Dunnett’s posttest was used after ANOVA to 
compare individual treatment groups (hIL-12 plus range concentrations of heparin) with a 
control group (hIL-12 alone). Statistical significance was accepted at the p ≤ 0.05 level. All 
analyses were conducted using GraphPad Prism 7 software (GraphPad Software, CA).  
3.3. Results 
3.3.1. Heparin modulates hIL-12 bioactivity in a dose-dependent manner.  
The effect of heparin concentration on hIL-12 activity was quantified via IFN- 
production by NK-92MI cells, activated human T cells or by activation of signaling in HEK-
BlueTM IL-12 cells. There was a significant increase of IFN- production or SEAP production in 
response to hIL-12 with increasing heparin concentrations in NK-92MI, T cells or HEK-BlueTM 
IL-12 cells  (p<0.0001 via one-way ANOVA). In detail, IFN- production by NK-92MI cells in 
response to 200 pg/mL hIL-12 more than doubled from 4438 ± 479 to 7876 ± 395 pg/mL as 
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exogenous heparin concentration increased from 0 g/mL to 25 g/mL (Fig. 3.1A) (p<0.0001 
via Tukey’s posttest). Additional heparin, beyond 25 g/mL, produced no further increase in 
hIL-12 activity, indicating a potential plateau. HEK-BlueTM IL-12 cells and T cells responded 
similarly with increasing levels of heparin inducing enhanced hIL-12 bioactivity (Fig. 3.1B,C). 
At very high heparin concentrations (500 g/mL vs. 25 g/mL), there was a decrease in hIL-12 
bioactivity in the HEK-BlueTM IL-12 cells indicating a possible inhibitory effect (p=0.0029 for 
500 g/mL vs. 25 g/mL heparin via Tukey’s posttest). 
Unlike in the human system, heparin did not enhance the activity of mIL-12 on either 
murine 2D6 cells (Fig. 3.1D) or splenocytes isolated from C57BL/6J mice (Fig. 3.1E). 
Interestingly, heparin significantly enhanced the activity of mIL-12 on human NK-92MI cells 
(Fig. 3.1F). Heparin facilitated a 1.55-fold increase in mIL-12 function on human NK cells 
which was greater than the heparin-induced increase in hIL-12 function on human NK cells. hIL-
12 was not active in the murine 2D6 cell line with or without heparin (Fig. 3.1D-F). 
3.3.2. Heparin does not facilitate non-canonical hIL-12 signaling 
IFN- expression is a key indicator of hIL-12 bioactivity. However, it is possible that 
heparin facilitated expression of other T helper cytokines via non-canonical signaling. Thus, we 
investigated the production of prototype Th1, Th2 and Th17 cytokines by NK-92MI cells and 
activated T cells exposed to hIL-12 with and without exogenous heparin. As expected, in 
response to hIL-12 alone, NK-92MI cells secreted high levels of IFN- (663.54.9 pg/mL) 
whereas heparin had no effect (Fig. 3.2A). Treatment with hIL-12 alone also increased the 
production of IL-10 and IL-6 by NK-92MI cells, which was similarly reported by another group 
(30). Upon addition of heparin, NK-92MI significantly increased production of IFN-, IL-10 and 
IL-6 by 1.26, 1.47 and 1.92-fold (Fig. 3.2A), respectively. It should be noted that IL-2 was 
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detected in all treatment groups because the NK-92MI cell line is stably transfected with the IL-2 
gene to maintain consistent cell proliferation (31). The amount of IL-2 did not change 
significantly with the addition of heparin. NK-92MI did not produce significant amounts of 
TNF, IL-4 or IL-17A regardless of heparin treatment (Supplementary Fig. S.3.3A,C). These 
cytokines are not normally produced in response to IL-12. Any expression in the presence of 
heparin would have indicated non-canonical signaling. A similar analysis showed that, activated 
T cells produced 626.82.4 pg/mL of IFN- in response to hIL-12. This was increased to 
1031.927.9 pg/mL when heparin was included (Fig. 3.2B). Like NK-92MI cells, no cytokine 
other than IFN- was secreted by activated T cells in response to heparin, hIL-12 or their 
combination (Supplementary Fig. S.3.3B,D).  
To validate IFN- production measured by cytokine profiling analysis, we investigated 
the intracellular expression of IFN- by CD4+ T cells, CD8+ T cells, CD56+ cells in PBMCs and 
NK92-MI cells in response to hIL-12 alone and hIL-12 plus heparin (Fig. 3.2C-E). The results 
showed that the combination of hIL-12 and heparin increased the percentages of cells producing 
IFN- over hIL-12 alone (CD4+ T cells: from 2.6330.291% to 4.2070.522%; CD8+ T cells:  
from 1.7570.378% to 3.597 0.616%; CD56+ NK cells:  from 2.2930.040% to 3.103  
0.496%; NK-92MI cells: from 1.473 0.163% to 9.8100.132%) (p<0.05 hIL-12 alone vs. hIL-
12 plus heparin via two-tailed t test) (Fig. 3.2C-E). 
3.3.3. Half-maximal effective concentration of IL-12 is reduced by heparin 
The ability of heparin to reduce the half-maximal effective concentration (EC50) of IL-12 
was quantified in NK-92MI cells, T cells and PBMCs. Supernatants from cells treated with 
increasing concentrations of hIL-12, with or without heparin, showed a typical sigmoidal dose-
response relationship (Fig. 3.3). For NK-92MI cells, the EC50 values for IL-12 alone and IL-12 
 90 
with heparin were 27.67 pg/mL and 2.34 pg/mL, respectively. Based on this result, heparin 
decreased the EC50 of IL-12 by 11.8-fold. Similar results were observed on T cells showed a 
reduction in EC50 value of hIL-12 from 61.71 pg/mL to 44.71 pg/mL, or 1.4-fold, and PBMCs 
showed a reduction in EC50 from 121.9 pg/mL to 13.76 pg/mL, or 8.9-fold, respectively. 
3.3.4. Effect of heparin chain length on IL-12 binding 
ITC measures the binding affinity and binding stoichiometry of protein-ligand 
interactions under well-defined conditions. The interactions of heparin with mIL-12 and hIL-12 
are exothermic. Under the experimental conditions used, the binding isotherms are observed to 
be hyperbolic and heparin binds to both hIL-12 and mIL-12 nearly in a 1:1 stoichiometry. 
Analysis of ITC data indicate that the binding affinity (Kd(apparent)) of heparin – IL12 interaction is 
strongly influenced by the chain length of heparin (Supplementary Fig. S.3.4). Specifically, 
heparin oligosaccharides with lesser than six saccharide units, like heparin di-, tetra-, and 
hexasaccharide, do not bind measurably to either hIL-12 or mIL-12 (Table 3.1).  Heparin 
octasaccharide shows reasonably strong binding (Kd(apparent) = 39 μM ) to hIL-12 but not to mIL-
12 (Table 3.1 and Supplementary Fig. S.3.4). The binding affinities of longer chain length 
heparin oligosaccharides, heparin decasaccharide and heparin dodesaccharide, to IL-12 are the 
strongest and range from 5.3 M to 8.6 M (Table 3.1). The binding affinities of hIL-12 and 
mIL-12 to LMWH, which is a polydisperse mixture of heparin with varying lengths of 
saccharide units, are ~10 μM and ~ 44 μM, respectively.  
In summary, ITC data suggest that hIL-12, in general, exhibits slightly higher binding 
affinity to heparin than mIL-12. In addition, the binding affinity between hIL-12 and heparin is 
strongly dependent on heparin chain length and plateaus at 10 to 12 saccharide units. 
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3.3.5. Heparin-induced modulation of hIL-12 bioactivity is dependent on heparin’s  
chain length 
The effect of heparin’s chain length on hIL-12 bioactivity was investigated in NK-92MI 
cells and HEK-BlueTM IL-12 cells. IFN- production data from NK-92MI cells showed that 
tetrasaccharides did not enhance hIL-12 bioactivity while hexasaccharides generated a modest 
enhancing effect (Fig. 3.4B). Interestingly, octasaccharides, decasaccharides, and 
dodecasaccharides produced similar enhancements in hIL-12 bioactivity to LMWH, which is 
typically 15 to 25 saccharide units (average molecular weight: 4 - 6 kDa) (Fig. 3.4B). Similar 
effects were observed with HEK-BlueTM IL-12 cells as only octasaccharides, decasaccharides 
and dodecasaccharides increased hIL-12 activity. 
3.3.6. Effect of sulfation on hIL-12 binding 
To determine how sulfation level affects heparin binding to hIL-12, a novel microarray 
approach was used. Fifty-two HS-derived compounds were synthesized with 1, 2 or 3 sulfate 
groups per disaccharide unit ranging in size from 5 to 18 saccharides (Fig. 3.5A). The 
compounds were arrayed on a slide and treated with fluorescence-labeled hIL-12. After rinsing, 
fluorescence analysis was performed to quantify levels of IL-12 binding to each of the HS-
derived compounds. Our analysis revealed that the highest amounts of hIL-12 were bound to 
heparin-derived compounds 18 and 19, which are dodecasaccharides containing 3 sulfate groups 
per disaccharide unit (Fig. 3.5B). Other sulfated HS-derived compounds also bound and retained 
hIL-12, however at lower levels. 
3.3.7. Sulfation is essential for HS-induced modulation of hIL-12 bioactivity 
To determine the effect of sulfation level on the HS-induced modulation of hIL-12 
bioactivity, selected heparan sulfate dodecasaccharides containing 1, 2 or 3 sulfate groups per 
disaccharide unit (Fig. 3.5A) were formulated with hIL-12 for treatment on NK-92MI and HEK-
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BlueTM IL-12 cells. Data from NK-92MI cells showed that compounds 21, 24 and 25, which 
contained less than 3 sulfate groups per disaccharide did not enhance hIL-12 bioactivity (Fig. 
3.5C) (p>0.05 in comparison of IL-12 alone vs. IL-12 plus compounds 21, 24, and 25 via 
Tukey’s posttest). On the other hand, compounds 18 and 19, which consisted of 3 sulfate groups 
per disaccharide unit, significantly enhanced hIL-12 bioactivity to levels similar to LMWH 
(p<0.0001 in comparison of IL-12 alone vs. IL-12 plus compounds 18, 19, and LMWH via 
Tukey’s posttest). Data from HEK-BlueTM IL-12 cells exhibited similar phenomena in that hIL-
12 activity was only enhanced with compounds 18 and 19 (p<0.0001 in comparison of IL-12 
alone vs. IL-12 plus compounds 18, 19, and LMWH via Tukey’s posttest). It should be noted 
that compound 23 produced different effects on IL-12 bioactivity in NK-92MI cells (p<0.0001 
via Tukey’s posttest) and HEK blueTM IL-12 cells (p<0.0001 via Tukey’s posttest) indicating that 
certain HS enhancement phenomena may be cell dependent. 
3.3.8. Proposed model of heparin-stabilized hIL-12/hIL-12R complex 
The structure of hIL-12 was imported from the PDB archive (1F45) (Fig. 3.6A). The 
heparin docking function in ClusPro was used to identify two heparin-binding motifs on the p40 
subunit of hIL-12 (117LKDQKEPKNK126 and 276QVQGKSKREKK286) (Fig. 3.6A). These 
correlate with our previous in silico string analysis (10).  
Models of each receptor subunit were based on the solved structure of interleukin-6 
receptor subunit β with differences. hIL-12Rβ1 was also based on the structures of anosmin-1, 
leukemia inhibitory factor receptor, and insulin receptor. The structure of hIL-12Rβ2 was further 
detailed using homology to human receptor 2 protein tyrosine phosphatase sigma, chicken 
mdga1, and the ectodomain of the receptor protein tyrosine2 phosphatase mu. Each prediction 
showed high (>90%) confidence in the model. Heparin binding segments on receptor subunit 
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ECDs were predicted using ClusPro. The top scoring segment for each receptor subunit were 
identified and highlighted in the protein models (Fig. 3.6B,C).  
To determine the spatial relationship of the heparin-binding segments and the potential 
role of heparin in stabilizing ligand-receptor interactions, we constructed a model of the hIL-
12/hIL-12R complex using the available crystal structure of hIL-12 and its predicted binding to 
the ECDs (Fig. 3.6D,E). The predicted hIL-12/hIL-12R complex shows the heparin-binding 
motifs located on hIL-12 to be in close proximity to hIL-12Rβ1. Estimated distances from the 
heparin binding sites on hIL-12 to the putative heparin binding site on hIL-12Rβ1 were 14 and 
18 Å (Fig. 3.6F). For the hIL-12Rβ2 ECD, the heparin-binding site is facing away from the p35 
subunit of hIL-12. Consequently, the distances from the heparin binding sites on hIL-12 to the 
top scoring heparin binding site on hIL-12Rβ2 were longer at 43 and 75 Å. Based on the putative 
heparin binding sites, this model predicts that only heparin molecules of a certain size could 
simultaneously bind to both the IL-12 ligand and receptor. Using an average length of 4 
Angstroms per disaccharide, it becomes clear that only heparin molecules with chain lengths of 
4, 5 or 6 disaccharide units, i.e. 8, 10 or 12 saccharides, are able to bridge the heparin-binding 
domains. In addition, the increased binding and activities observed with higher sulfation levels 
indicate that the stabilization interaction is likely mediated by non-specific electrostatic 
interactions and not particular sulfation patterns. 
3.4. Discussion 
Our previous study was the first to demonstrate that sulfated GAGs, such as heparin and 
heparan sulfate, could enhance the bioactivity of hIL-12 (12). In this follow up study, we 
extended this research to identify the characteristics of heparin that were required to modulate 
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hIL-12 bioactivity. In doing so, we aimed to develop a working model capable of explaining the 
mechanism(s) of heparin-induced hIL-12 enhanced function. 
Initial studies to determine the optimal concentration of heparin found that, for most cell 
types, a maximal or plateau effect was achieved between 10 g/mL and 25 g/ml heparin (Fig. 
3.1). These concentrations are considered physiologically relevant as circulating levels of 
heparin in humans are 1 to 5 g/ml (32). During inflammation, , systemic concentrations of 
heparin and heparan sulfate are significantly increased (33, 34). Although, not explored, we 
hypothesize that local sites of inflammation have similar increases in heparin and heparan 
sulfate. 
Because our previous study demonstrated that heparin can recover IL-12 signaling in 
cells lacking functional IL-12 receptors (12), we hypothesized that IL-12 could be signaling 
through non-canonical pathways, perhaps via receptors associated with other IL-12 family 
members. However, our cytokine profiling analyses and intracellular cytokine staining showed 
that no other Th1, Th2 or Th17 cytokines were induced in the presence of heparin (Fig. 3.2). 
Heparin simply appears to make hIL-12 signaling more efficient by stabilizing the interaction of 
hIL-12 and hIL-12R. In particular, a greater percentage of lymphocytes respond to hIL-12 in the 
presence of heparin (Fig. 3.2C,D). Also, the EC50 data demonstrated that heparin can reduce the 
effective concentration of hIL-12 by 1.5 to 11.8-fold (Fig. 3.3).   
In terms of heparin characteristics, both chain length and sulfation level exhibited a 
threshold-type effect on hIL-12. Specifically, heparin molecules less than a threshold of 6 
saccharide units did not affect hIL-12 activity, while those above 8 saccharide units induced a 
bioactivity plateau that was similar to LMWH (Fig. 3.4). It should be noted that heparin 
hexasaccharides which only modestly enhanced hIL-12 activity, were not found bind strongly to 
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hIL-12 in ITC studies. This apparent discrepancy may be due to differences in sensitivity 
between the two approaches. ITC requires higher concentrations of heparin and hIL-12 while the 
limit of reliable detection of binding is on the order of a couple hundred M. Hexasaccharides 
binding to hIL-12 may be too weak to be detected but still strong enough to provide partial 
enhancement of hIL-12 activity.  Regarding sulfation level, HS with less than 3 sulfate groups 
per disaccharide did not significantly improve hIL-12 bioactivity. In contrast, both HS molecules 
containing 3 sulfate groups per disaccharide, compounds 18 and 19, showed improved hIL-12 
binding and bioactivity (Fig. 3.5). HS-derived molecules with less than 3 sulfate groups per 
disaccharide have lower negative charge densities which likely results in weaker interactions 
with both hIL-12 and hIL-12R. These data imply that the heparin-IL-12 interaction is a non-
specific electrostatic interaction as opposed to an interaction that depends on a particular 
sulfation pattern. The inability of poorly sulfated heparins to enhance hIL-12 bioactivity agreed 
with our previous data demonstrating that poorly or non-sulfated GAGs, e.g. chondroitin sulfate 
and hyaluronic acid, had no effect on hIL-12 bioactivity (12).  
Using the chain length data in particular, we hypothesized that heparin could be 
stabilizing the hIL-12/hIL-12R complex by binding to heparin-binding domains on both ligand 
and receptor. We reasoned that only heparin molecules of a sufficient size would be able to bind 
simultaneously to heparin-binding sites on different subunits of the complex. Our in silico 
analysis identified two major heparin-binding domains on hIL-12 as well as the top scoring 
heparin binding segments on each hIL-12R subunit (Fig. 3.6). When hIL-12 is bound to hIL-
12R, the distances between heparin-binding domains located on different proteins, i.e. hIL-12, 
hIL-12R1 and hIL-12R2, range from 14 to 75 Å. A tetrasaccharide, with a maximum distance 
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of approximately 16-17 Å between sulfate groups, would therefore have a lower probability of 
binding to and stabilizing the hIL-12/hIL-12R interactions than an octasaccharide or LMWH.     
It should be noted that the tertiary complex and the identified heparin binding domains on 
hIL-12, hIL-12R1 and hIL-12R2 are merely predictions at this point. Although, Garnier et al. 
demonstrated that truncation of the carboxyterminal domain on the p40 subunit to exclude the 
putative heparin binding segment located within amino acids 279 to 287 significantly reduced 
the heparin-binding ability of hIL-12 (11). Where exactly heparin binds to IL-12, both human 
and mouse, as well as each IL-12R subunit is the subject of ongoing crystallography work. Once 
completed, we will have a definitive picture of the heparin/IL-12/IL-12R quaternary complex. 
An observation that appears to agree with our stabilization hypothesis was that heparin 
did not improve mIL-12 bioactivity on mouse 2D6 cells, but significantly improved mIL-12 
bioactivity on human NK-92MI cells (Fig. 3.1). We hypothesize that the binding of mIL-12 to 
mIL-12R is of sufficient affinity such that heparin is not needed to enhance binding and 
signaling. On the other hand, the affinity of mIL-12 for hIL-12R is expected to be much lower 
than the affinity of mIL-12 for mIL-12R or hIL-12 for hIL-12R. Therefore, the benefit of adding 
heparin to stabilize the potentially ‘loose’ mIL-12/hIL-12R complex results in a robust 
enhancement of mIL-12 activity. In fact, the activity of mIL-12 was increased 1.55-fold, which 
was greater than heparin-induced enhancements for hIL-12 (1.18-fold) (Fig. 3.1D).  
Drawing from our previous work, heparin’s ability to stabilize weak IL-12/IL-12R 
interactions may be a key mechanism by which hIL-12 signaling was recovered in cells lacking 
functional hIL-12R (12). In these previous studies, hIL-12R1 and hIL-12R2 were functionally 
deleted via CRISPR/Cas9 genome editing. However, the Cas9-induced cleavage of the hIL-
12R1 and hIL-12R2 genes likely induced random mutations in the receptor subunits instead of 
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a complete knockout. The mutated hIL-12R did not bind hIL-12 sufficiently to allow signaling, 
however, the addition of heparin may have stabilized this ‘loose’ complex enough to recover 
hIL-12 bioactivity. Ongoing studies are aimed at understanding which portions of the hIL-12R 
subunits are critical for signaling in the presence and absence of heparin. We postulate that this 
research could lead to a new therapeutic option for patients with mutations in IL-12R1 that lead 
to Mendelian susceptibility to mycobacterial diseases (35, 36) (Appendix 1).  
Lastly, other heterodimeric cytokines of the IL-12 family have overlapping structural 
features (37), and therefore, could be modulated by heparin. In particular, IL-23 shares the p40 
subunit along with its cognate receptor IL-12R1 with IL-12. IL-35 shares p35 and IL-12R2 
with IL-12. Our preliminary data indicate that heparin’s enhancement of hIL-23 bioactivity is 
even more robust than its effects on hIL-12 (Appendix 2). Furthermore, heparin was found to 
inhibit the antagonist activity of p40 monomer and dimer in preliminary experiments (Appendix 
3). Given the diverse immunological functions of the IL-12 family, the impact of heparin as a 
regulator of immunity is of great interest.  
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Table 3.1. Binding affinities between hIL-12 or mIL-12 and heparin oligosaccharides or 
LMWH. 
 
 Tetra-
saccharide 
Hexa-
saccharide 
Octa-
saccharide 
Deca-
saccharide 
Dodeca-
saccharide 
LMWH 
hIL-12 NB NB 39 M 6.6 M 5.3 M 10 M 
mIL-12 NB NB NB 5.7 M 8.6 M 44 M 
 
NB: no binding observed  
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Figure 3.1. IL-12 bioactivity is modulated by heparin in a dose-dependent manner. The 
production of IFN- by (A) NK-92MI cells or (B) Human T cells or (C) alkaline phosphatase by 
HEK-BlueTM IL-12 cells was measured after exposure to a fixed concentration of hIL-12, 200 
pg/ml for (A) and (B), or 1 ng/ml for (C), and increasing concentrations of heparin.  (D) The 
Mouse IL-12 (200 pg/mL)
Human IL-12 (200 pg/mL)
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proliferation of mIL-12 sensitive 2D6 cells in response to mIL-12 and hIL-12 with increasing 
heparin concentrations was indirectly assessed via CellTiter-Glo® 3D Cell Viability Assay. IFN-
 production by (E) murine splenocytes isolated from C57BL/6J mouse, and (F) NK-92MI cells 
in response to mIL-12 and hIL-12 with increasing heparin concentrations was measure via 
ELISA. Asterisks indicate a significant difference between the treatments of IL-12 alone and IL-
12 plus increasing heparin concentrations (**=p<0.01 and ***=p<0.001 via one-way ANOVA: 
solid lines), ns: not significant. The comparison of IL-12 bioactivity in response to hIL-12 alone 
and different heparin concentrations plus hIL-12 (200 pg/mL) was evaluated by Dunnett’s 
posttest (dashed lines). Data points represent mean ± standard deviation of triplicate 
measurements. Experiments were performed in triplicate and repeated three times with similar 
results. 
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Figure 3.2. Heparin amplifies hIL-12-induced cytokine profiles. 
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Figure 3.2. Heparin amplifies hIL-12-induced cytokine profiles. 
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Figure 3.2. Heparin amplifies hIL-12-induced cytokine profiles. The secretion of prototypical 
Th1, Th2 and Th17 cytokines by (A) NK-92MI cells and (B) activated T cells in response to hIL-
12 (200 pg/mL) in the presence and absence of heparin (10 g/mL) were analyzed via a BD 
CBA kit. Heparin alone does not alter baseline cytokine production while the addition of heparin 
to hIL-12 increases the amount, but does not alter the type, of cytokine expressed by NK or T 
cells. Columns represent mean ± standard deviation of triplicate measurements. (A), (B) *p<0.05 
for one-way ANOVA comparing all treatment groups. **p<0.05 for Tukey’s posttest comparing 
hIL-12 alone and hIL-12 plus heparin. (C) Dot plots describe positive percentages of intracellular 
IFN- in NK-92MI cells, CD4+ T cells, CD8+ T cells, and NK cells for comparison of hIL-12 
alone and hIL-12 plus heparin (*p<0.05, **p<0.01, ***p<0.0001 via two-tailed t test). (D) Dot 
plots show representative intracellular expression of IFN- by gated CD3+CD4+ T cells, 
CD3+CD8+ T cells, and CD3-CD56+ NK cells from PBMCs in four experimental groups (fresh 
media, heparin, hIL-12, hIL-12 plus heparin). (E) Dot plots show representative intracellular 
expression of IFN- by gated CD56+ NK92-MI cells in four experimental groups (media, 
heparin, hIL-12, hIL-12 plus heparin). Experiments were performed in triplicate and repeated 
three times with similar results.  
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Figure 3.3. Heparin decreases the EC50 value of hIL-12. hIL-12 bioactivity curves showing 
the IFN- production by (A) NK-92MI cells, (B) human PBMCs, and (C) human T cells exposed 
to increasing hIL-12 in the presence and absence of heparin (10 g/mL). The EC50 values of hIL-
12 for NK-92MI cells and human PBMCs were significantly decreased by heparin (p<0.0001 vs. 
hIL-12 alone via extra sum-of-squares F test). All data points represent mean ± standard 
deviation of triplicate measurements. Experiments were performed in triplicate and repeated 
three times with similar results. 
 
No heparin With heparin (10 µg/mL)
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Figure 3.4. Modulatory activity is dependent on heparin chain length. hIL-12 activity as 
measured by (A) IFN- production by NK-92MI cells or (B) secreted alkaline phosphatase by 
HEK-BlueTM IL-12 cells was measured after co-culture with heparin oligosaccharides or LMWH 
(10 g/mL). Heparin octasaccharide, decasaccharide, dodecasaccharide, and LMWH 
significantly increased the bioactivity of IL-12 in NK-92MI cells and HEKTM blue IL-12 cells 
(***p<0.0001 vs. hIL-12 alone via two-way ANOVA). Heparin tetrasaccharide did not increase 
the bioactivity of hIL-12 in NK-92MI cells (p>0.05 vs. hIL-12 alone via Tukey’s posttest) and 
HEKTM blue IL-12 cells (p<0.0001 vs. hIL-12 alone via Tukey’s posttest). Heparin 
hexasaccharide increased the bioactivity of hIL-12 in NK-92MI cells (p<0.0001 vs. hIL-12 
alone, p<0.01 vs. hIL-12 plus LMWH via Tukey’s posttest), and showed no effect on hIL-12 
bioactivity in HEKTM blue IL-12 cells (p>0.05 vs. hIL-12 alone via Tukey’s posttest). Columns 
represent mean ± standard deviation of triplicate measurements. Experiments were performed in 
triplicate and repeated three times with similar results.  
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Figure 3.5. Heparin-induced enhancement of hIL-12 depends on sulfation level 
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Figure 3.5. HS-induced enhancement of hIL-12 depends on sulfation level. hIL-12 binding to 
HS oligosaccharides was quantified via a novel microarray. (A) Fifty-three unique HS constructs 
were synthesized to provide a range of lengths and sulfation levels. Abbreviations: GlcNAc: N-
acetylglucosamine; GlcNS: N-sulfated glucosamine; GlcA: glucuronic acid; IdoA2S: 2-O-sulfo-
α-L-iduronic acid; 6S: 6-O-sulfate. (B) The binding of Alexa Fluor 488-labeled hIL-12 to the 
different heparin oligosaccharides was visualized and quantified via fluorescence microscopy. 
Six dodecasaccharides, including the high binding compounds 18 and 19, were selected for 
bioactivity studies. hIL-12 activity as determined by (C) IFN- production by NK-92MI cells or 
(D) secreted alkaline phosphatase by HEK-BlueTM IL-12 cells was measured after co-culture 
with heparin compounds 18, 19, 21, 23, 24, 25 or LMWH (10 g/mL). Heparin compounds 18, 
19, and LMWH significantly increased the bioactivity of hIL-12 in NK-92MI cells and HEK-
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BlueTM IL-12 cells (p<0.0001 vs. hIL-12 alone via Tukey’s posttest). Heparin compounds 21, 24, 
25 did not enhance the bioactivity of IL-12 in NK-92MI cells and HEK-BlueTM IL-12 cells 
(p>0.05 vs. hIL-12 alone via Tukey’s posttest). Heparin compound 23 did not enhance hIL-12 
bioactivity in NK-92MI cells (***p<0.0001 vs. IL-12 alone via Tukey’s posttest) and modestly 
enhance IL-12 bioactivity in HEK-BlueTM IL-12 cells (p<0.0001 vs. IL-12 alone, p<0.0001 vs. 
IL-12 plus LMWH via Tukey’s posttest). Data bars in the bioactivity studies represent mean ± 
standard deviation of triplicate measurements. Experiments were performed in triplicate and 
repeated three times with similar results. 
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Figure 3.6. Heparin may stabilize the interactions of hIL-12 with hIL-12R1 and hIL-
12R2. (A) Heparin-binding motifs (red) on hIL-12 (PDB: 1F45) were identified in ClusPro as 
117LKDQKEPKNK126 and 276QVQGKSKREKK286. The ECD structures of (B) hIL-12R1 and 
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(C) hIL-12R2 were modeled in PyMOL. As with hIL-12, heparin-binding segments for each 
receptor subunit were identified in ClusPro. The top scoring segment for each subunit is 
highlighted (red). (D) A model of the hIL-12/hIL-12R complex was predicted using PyMOL and 
ClusPro. Two views of the model, nearly 180 degrees rotated around the vertical axis, relate the 
locations of the heparin binding segments (red). (E) Estimated distances from each of the heparin 
binding sites on hIL-12 to the putative heparin binding sites on the receptor subunits were 
calculated using PyMol’s Measurement tool. 
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Supplementary Figure S.3.1. Gating strategies for CD4+ T cells, CD8+ T cells, CD56+ NK 
cells from PBMCs. Lymphocytes for analysis of CD4+ T cells, CD8+ T cells, and NK cells were 
gated based on using forward scatter (FSC)/side scatter (SSC) dot plots. Single cells were gated 
based on FSC-H and FSC-A dot plots. T cells were gated from lymphocytes based on dot plots 
SSC/CD3. From the T cell (CD3+) gate, CD4+ and CD8+ T cells were gated based on CD8/CD4 
dot plots. From the non-T cell (CD3-) gate, NK cells (CD3-/CD56+) were gated based on 
SSC/CD56 dot plots. 
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Supplementary Figure S.3.2. Gating strategy for NK-92MI cells. Single cells were gated 
based on FSC-H and FSC-A dot plots. NK-92MI cells were gated based on using FSC-A/SSC-A 
and FSC-A/CD56+ dot plots. 
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Supplementary Figure S.3.3. Cytokine profiles produced by NK-92MI cells and activated T 
cells in response to media alone, heparin alone, hIL-12 alone, or with both reagents. 
Cytometric bead array (CBA) dot plots showing the secretion of 7 cytokines including IL-2, IL-
4, IL-6, IL-10, TNF, IFN-, and IL-17A from (A) NK-92MI cells or (B) Human T cells. Bar 
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graph showing the secretion of cytokines including IL-4 from (C) NK-92MI cells, and the 
production of IL-2, IL-4, IL-6, IL-10, TNF and IL-17A from (D) Human T cells (p>0.05 in the 
comparison of IFN- production induced by 4 conditions via one-way ANOVA). 
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Supplementary Figure S.3.4. Isothermograms for hIL-12 or mIL-12 interactions with 
heparin. Isothermograms describe binding interactions between heparin and (A) hIL-12 or (B) 
mIL-12. The upper panel of each isothermogram shows the raw data obtained for each of the 30 
injections. The lower panels display the best fit data to one-set of sites binding model using 
OriginTM v7.0 software.  
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
4.1. Significant findings of this dissertation 
 Previous work from our lab has shown that IL-12 is a specific heparin-binding protein 
(1). The overarching goal of this research was to investigate if the interaction between heparin 
and IL-12 influenced the immunobiology of IL-12. In particular, we sought to explore the 
molecular consequences of heparin-IL-12 interaction, the biological outcomes of the interaction 
as well as the mechanisms responsible for these outcomes. The completed research has led to the 
following significant findings: [1] heparin increases IL-12 activity in human but not mouse 
lymphocytes; [2] heparin modestly protects IL-12 from proteolytic degradation; [3] heparin 
canonically amplifies IL-12-induced cytokine production by activated lymphocytes; [4] heparin-
induced modulation of IL-12 bioactivity is dependent on heparin concentration, chain length and 
sulfation; [5] heparin likely stabilizes the interaction between IL-12 and IL-12R for which we 
have developed a model of stabilization; and [6] heparin is capable of enhancing IL-12 signaling 
in IL-12R1deficient cells. Each of these findings is detailed below. 
4.1.1. Heparin increases IL-12 activity in human but not mouse 
IL-12 plays central role in the immune system by connecting the activities of innate and 
adaptive immunity (2). Due to this potent activity, IL-12 has been used in clinical trials for the 
treatment of cancer and HIV infection (3-5). We and others have identified likely heparin 
binding-domains on the p40 subunit of IL-12 (1, 6). Recently, we found that heparin binds to IL-
12 with low micromolar affinity (Table 2.1) (1, 7). Thus, we first questioned if the binding 
between IL-12 and heparin plays a role in the physiological function of hIL-12 – a 
 121 
powerful proinflammatory cytokine with immunoregulatory abilities. Our data revealed that 
heparin increased the biological activity of hIL-12 by up to 6 fold (7). Significantly, the 
enhancing effect of heparin on IL-12 bioactivity only occurred in human cells (NK-92MI cells, 
human T cells, human PBMCs, and HEK-BlueTM cells), but not in murine cells (2D6 cells and 
splenocytes isolated from C57BL/6J mice). Interestingly, heparin was found to bind to both mIL-
12 and hIL-12 with similar binding affinity (Table 3.1). Thus, we suspect that the mIL-12/mIL-
12R interaction is of sufficient affinity such that heparin does not further enhance the interaction. 
On the other hand, the affinities of mIL-12 for hIL-12R and hIL-12 for hIL-12R are likely much 
lower than the affinity of mIL-12 for mIL-12R. Therefore, the benefit of adding heparin to 
stabilize the potentially ‘loose’ mIL-12/hIL-12R and hIL-12/hIL-12R complex resulted in a 
robust enhancement of mIL-12 activity. Planned research will test this hypothesis by producing 
recombinant proteins of the extracellular domain of human and mouse IL-12R in order to 
measure the binding affinities of 3 complexes including mIL-12/mIL-12R, mIL-12/hIL-12R, and 
hIL-12/hIL-12R in the presence and absence of heparin. 
4.1.2. Heparin binds to IL-12 and prevents IL-12 from proteolytic degradation 
In collaboration with Dr. Suresh Kumar’s lab at the University of Arkansas-Fayetteville, 
we examined the molecular consequences of heparin-hIL-12 binding by several biochemical 
approaches. Using isothermal calorimetry to analyze the interaction of hIL-12 and 
heparin/heparan sulfate, we demonstrated that hIL-12 likely contains a single distinct, accessible 
binding pocket for heparin/heparan sulfate which could lead to dimerization of hIL-12. Other 
interleukins are able to increase the binding affinity to their receptors when cytokines form dimer 
or tetramer structures. For instance, homodimer forms of IL-5 are able to bind its extracellular 
domain of IL-5Rα and arrange in a critical “wrench-like” structural conformation (8). Similarly, 
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dimers or tetramers of IL-22 were shown to arrange into a V-shaped conformation binding to IL-
22R1 receptor (9).  
Furthermore, heparin has been shown to protect proteins from the proteolytic degradation 
of proteases present in the extracellular environment (10-13). We exposed hIL-12, with and 
without heparin, to various levels of proteolytic degradation from proteases in spent media to a 
protease cocktail containing trypsin, chymotrypsin, thrombin and thermolysin. For using spent 
media as a source of proteases, hIL-12 was not significantly degraded in spent media while 
heparin was found to prevent the proteolytic degradation of IL-12 in the protease cocktail by up 
to 14% within 30 minutes of incubation. Although heparin can slightly prevent hIL-12 from 
strong proteolytic degradation, this is unlikely to explain the enhanced hIL-12 biological activity 
in vitro that we discovered. 
4.1.3. Heparin canonically amplifies IL-12 activity 
 Data in Chapter 2 highlight the ability of heparin to recover IL-12 bioactivity in cells 
expressing mutant forms of IL-12 receptors that were poorly active (Fig. 2.5). We proposed that 
heparin’s interactions with IL-12 could activate  a novel signaling pathway leading to the 
enhanced production of IFN- as well as other cytokines. Using a cytometric bead array (CBA) 
to measure production of the prototypical cytokines produced by the three major T helper cell 
classes, we showed that heparin only amplifies the bioactivity of IL-12, and does not trigger 
another signaling pathway. One limitation of this study is that the CBA assay evaluates only 7 
cytokines related to Th1, Th2 and Th17 responses. Other cytokines and signaling pathways may 
be altered in the presence of heparin. For a more comprehensive analysis, higher level multiplex 
assays, such as Luminex RNA-sequencing and/or kinase profiling can be employed.  
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4.1.4. Heparin-induced modulation of IL-12 bioactivity is dependent on heparin 
concentration, chain length and sulfation 
We have shown that sulfated GAGs including heparin and heparan sulfate could bind and 
enhance biological activity of hIL-12 (1, 7). However, the exact molecular mechanisms of this 
modulation still remain unclear. Thus, we extended our previous study to investigate 
characteristics of heparin that play essential roles in its modulation to hIL-12 bioactivity. In 
Chapter 3, we investigated three characteristics of heparin that might play a role in modulating 
IL-12 bioactivity including heparin concentration, chain length, and sulfation level. First, we 
found that concentrations of heparin ranging from 10 g/mL to 25 g/mL produce maximal 
effect on the enhancement of IL-12 bioactivity. The next investigation of heparin characteristics 
showed that heparin molecules less than a threshold of 6 saccharide units do not influence hIL-
12 activity, while those above 8 saccharide units induce a bioactivity plateau that is similar to 
low molecular weight heparin. Likewise, heparins with less than 3 sulfate groups per 
disaccharide do not significantly improve hIL-12 bioactivity. In contrast, heparin molecules 
containing 3 sulfate groups showed improved hIL-12 binding and bioactivity. Interestingly, the 
inability of poorly sulfated heparins to enhance hIL-12 bioactivity agreed with our previous data 
in chapter 2 demonstrating that poorly or non-sulfated GAGs, e.g. chondroitin sulfate and 
hyaluronic acid, has no effect on hIL-12 bioactivity (7).  
4.1.5. The development of a working model of stabilization showing the interaction 
of heparin – IL-12 and IL-12R 
We have shown that heparin clearly increases the concentration of hIL-12 at cell surfaces 
by using a flow cytometry analysis of hIL-12 conjugated with a fluorescent tag (7). This result 
suggested that exogenous heparin is able to maintain a reservoir of hIL-12 at the cell surface. To 
elucidate how heparin could retain high concentrations of IL-12 at cell surfaces, we proposed a 
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working model capable of describing how heparin interacts with IL-12 and IL-12 receptors. 
Using an in silico analysis, we point out 4 putative binding sites of heparin on hIL-12 and hIL-12 
receptors with 2 sites located in p40 subunit of hIL-12, 1 site located in hIL-12R1, and 1 site 
located in hIL-12R2. Thus, we proposed that heparin serves as a co-receptor of IL-12 and IL-12 
receptors by simultaneously binding to heparin-binding sites on both ligand and receptors. By 
using this working model, we could explain the effect of heparin chain length on IL-12 
bioactivity. When IL-12 is bound to IL-12R, the distances between heparin-binding domains 
located on different proteins ranging from 14 to 75 Å. A tetrasaccharide, with a maximum 
distance of approximately 16-17 Å between sulfate groups, would therefore have a lower 
probability of binding to and stabilizing the hIL-12/hIL-12R interactions than an octasaccharide 
or LMWH.  
4.1.6. Heparin is capable of enhancing IL-12 signaling in IL-12R1deficient cells 
In Chapter 2, we showed that heparin is able to recover the bioactivity of IL-12 in cells 
expressing mutant forms of IL-12R that were poorly active. With the model of stabilization 
proposed in Chapter 3, we sought to explore the mechanism of IL-12 recovery in the presence of 
heparin. Thus, we investigated the effect of heparin on IL-12 activity in 2 cell-based models that 
lack normal IL-12R1 expression including IL-12R1 deficient PBMCs from MSMD patients as 
well as IL-12R1 mutant NK-92MI cells. We showed that heparin enhanced the production of 
IFN- in response to IL-12 in PBMCs isolated from 4 of 6 MSMD patients. We also found that 
heparin recovers the bioactivity of IL-12 in multiple clones of IL-12R1 mutant NK-92MI cells. 
However, the effect of heparin plus IL-12 in these cell clones still remains unclear because 
although IL-12R1 expression was reduced, a wild-type sequence was found in all developed 
clones while a CRISPR-induced mutation could not be verified. Furthermore, we could not rule 
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out the possibility of off-target effects induced by CRISPR/Cas9. Studies of heparin induced IL-
12 acitivty in IL-12Rb1-deficient cells produced two hypotheses. First, the IL-12Rb1 cells in 
which IL-12 activity is enhanced by heparin are ‘leaky’ and contain low levels of wild type IL-
12R1. Second, all IL-12 signaling is mediated through IL-12R2 alone. These data as well as 
the above analyses are provided in the Appendix 1 of this dissertation. 
4.2. Concluding remarks 
Results from these studies clearly show a physiological function of heparin in IL-12 
immunobiology. The observation of increased hIL-12 bioactivity by heparin is rare among other 
interleukins, for which heparin binding is typically more inhibitory/neutral than augmentative. A 
plausible physiological explanation for interaction of IL-12 and heparin is to retain IL-12 at 
specific sites. IL-12 is recognized to induce life-threatening adverse events when systemically 
administered (14). Heparin is released by mast cells and basophils that are typically recruited to 
inflammation sites (15-17). Thus, the localization of IL-12 and enhancement of its bioactivity by 
heparin at inflammation sites may provide a way to limit the systemic toxicity of this powerful 
cytokine. There are lines of evidence showing that other pro-inflammatory cytokines, e.g. TNF-
, IL-1, or GM-CSF, are able to bind to heparin (18-20). Thus, these findings support the 
paradigm of heparin-induced localization of proinflammatory cytokines at inflammation sites. 
The fact that heparin also makes IL-12 more effective at these sites may represent a positive 
feedback mechanism for cell-mediated immune responses.  
4.3. Future directions 
Our future research will address three unanswered questions including: [1] does heparin 
stabilize the complex of IL-12 and IL-12R? [2] how does heparin recover IL-12 bioactivity in 
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IL-12R1 deficient cells including MSMD patient cells and engineered NK-92MI cells? [3] is 
heparin-induced modulation of IL-12 bioactivity physically relevant? 
First, to investigate if heparin stabilizes the complex of IL-12 and IL-12R, we are 
planning to produce recombinant proteins of the extracellular domains (ECDs) of human and 
murine IL-12R1 and IL-12R2. These ECDs will help us to determine the binding strength of 
IL-12 to its receptors in the presence or absence of heparin via ITC. Moreover, we can compare 
the binding affinity of 2 complexes consisting of heparin/hIL-12/hIL-12R1/hIL-12R2 and 
heparin/mIL-12/mIL-12R1/mIL-12R2 that could explain why heparin binds to both mIL-12 
and hIL-12, but only helps increasing the bioactivity of hIL-12 and mIL-12 on human derived 
cells. Related to this work, we are also pursuing crystallography work, in collaboration with Dr. 
Lars Pedersen at the National Institute of Environmental Health Sciences, to visualize and 
confirm the interaction between IL-12 receptors and IL-12 and/or heparin at an atomic level. X-
ray crystallographic studies will show how the proteins interact with heparin, and any differences 
in the conformation of the IL-12 receptors when bound by IL-12 in the presence or absence of 
heparin. In addition, this study will be the first to provide atomic-level resolution of ECDs of IL-
12 receptors. 
Second, we seek to explore the molecular mechanisms underlying heparin-induced 
recovery of IL-12 bioactivity in MSMD patient cells. As mentioned above, studies to date have 
generated two hypotheses that can account for heparin-enhanced IL-12 activity in IL-12R1 
deficient cells. Because we hypothesized that heparin and IL-12 might signal through IL-122 
receptor, thus we will investigate the downstream signaling of IL-12R2. We will measure the 
phosphorylation of JAK2 and STAT4 in IL-12 plus heparin-induced MSMD patient cells 
because these two proteins are downstream targets of IL-12R2 (21). To determine if heparin 
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can facilitate IL-12 signaling through IL-12R2 alone, a cell line containing only IL-12R2 can 
be generated. Similar cell lines have been created by our collaborators at Rockefeller University. 
There are several precedents of heterodimeric cytokines that can signal through single subunit 
chain receptors, whereas they conventionally bind to 2 different subunit receptors (9, 23). To 
evaluate the potential ‘leakiness’ of IL-12R1 mutant cells, intracellular staining of activated T 
cells from responding MSMD patients can be used to sort IFN- expressing cells. The mRNA 
from these cells can then be isolated, amplified and sequenced to determine if wild-type 
constructs are indeed produced. 
Even though CRISPR-induced IL-12R1 mutations were not confirmed in mutant NK-
92MI cells, this cell line remains valuable for future exploration. Future studies will focus on 
using CRISPR/Cas9 homology-directed repair to create a library of mutant NK-92MI with IL-
12R1 mutations matching the breadth of those observed in MSMD patients. By using Cas9 
protein instead of Cas9 encoded plasmids, we can reduce the possibility of continuous expression 
of Cas9 that results in introduction of undesired off-targets and mutations. Using a homology 
template, specific mutations can be introduced to the IL-12R1 gene with high accuracy. 
Mutations matching those discovered in MSMD patients can be developed. Furthermore, this 
technology can also be used to disrupt and determine the influence of the heparin binding 
domains on IL-12R1 or IL-12R2.  
Lastly, the interaction of IL-12 and heparin are likely to help retain IL-12 at a site of 
inflammation rather than allowing potentially toxicity systemic dissemination of IL-12. To 
explore this possibility, the presence of endogenous heparin and heparin sulfate at inflammation 
sites must be quantified. Mast cells, the primary producers of heparin, have been found to 
accumulate in tumors during cancer progression (24). The mast cell-deficient mouse model most 
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widely used is WBB6F1- KitW/W-v ; these mice are  commercially available (25). Thus, the 
production of heparin in tumors in wild-type mouse model and mast cell-deficient mice can be 
compared. If a difference in heparin production between these mouse models is found, then the 
local retention and bioactivity of injected IL-12 in these tumors can be explored. If there is no 
difference in heparin or heparan sulfate concentrations in tumors of wild-type and mast cell 
deficient mice, then other types of infection and inflammation can be explored.  
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APPENDIX 1: EFFECTS OF HEPARIN ON IL-12 BIOACTIVITY IN IL-12 RECEPTOR 
SUBUNIT BETA 1 DEFICIENT CELLS 
Introduction 
 IL-12 is a heterodimeric cytokine comprised of two disulfide-linked glycoprotein 
subunits, p35 and p40 (1-3). The IL-12 receptor similarly consists of heterodimeric subunits with 
the IL-12 receptor β1 (IL-12R1) chain binding p40 and the IL-12 receptor β2 (IL-12R2) chain 
binding p35 (4, 5). Binding of IL-12 by IL-12R activates Janus kinase 2 (JAK2) and tyrosine 
kinase 2 (TYK2), leading to the phosphorylation of signal transducers and activators of 
transcription 3 (STAT3) and STAT4. Homodimers of phosphorylated STAT4 (pSTAT4) 
translocate to the nucleus where they bind to promoters of IL-12-responsive genes, including 
IFN-.  
Molecular defects in the IL-12 signaling pathway lead to defects in IFN- production 
which hinders an individual’s ability to mount cell-mediated immune responses. Patients with 
inborn errors in IL-12/IFN- immunity have difficulty controlling intracellular microorganisms 
and are diagnosed with Mendelian susceptibility to mycobacterial disease (MSMD). MSMD is 
categorized by vulnerability to poorly virulent mycobacterial infections such as BCG vaccines 
and environmental mycobacteria (6, 7). The severity of MSMD varies widely from 
asymptomatic, subclinical infections to severe, disseminated disease which can be lethal (8). A 
clinical study of 141 MSMD patients from 30 countries around the world revealed that the 
mortality rate was 29.78% and the mean age at death was 7.5 years in the 40 patients who died 
(ranges from 1.2 to 37.7 year, standard deviation 8.1 year) (9). The causes of death were 
disseminated BCG infection, nontuberculous mycobacteria, tuberculosis, or salmonellosis, 
concurrent M. avium and Salmonella infections, severe electrolyte disorder following diarrhea 
(9).  
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IL-12R1 deficiency is the most frequent known genetic etiology of MSMD. MSMD 
patients whose cells are deficient in IL-12R1 expression poorly respond to IL-12 and only 
release low amounts of IFN- in response to IL-12 (8, 9). Each subunit of IL-12R exhibits 
similar affinity for its respective IL-12 subunit. The affinity of p40 for IL-12R1 and p35 for IL-
12Rb2 are strong - Kd = 6 nM and 5 nM, respectively. However, when the IL-12 heterodimer is 
bound to both receptor subunits, the affinity is enhanced two orders of magnitude (Kd = 65 pM) 
(10). Thus, loss of IL-12R1 results in poor binding of IL-12 to IL-12R2 leading to impairment 
of IL-12 signaling.  
Our previous work demonstrated that heparin binds to and enhances the bioactivity of IL-
12 (11, 12). This effect was limited to heparin molecules longer than 4 disaccharide units. The 
requirement of longer chain lengths implied that heparin could simultaneously bind two proteins, 
e.g. IL-12 and IL-12R, thus stabilizing their interaction. Using an in silico analysis, we identified 
4 putative binding sites of heparin located in IL-12 and IL-12 receptors (2 sites on the p40 
subunit of IL-12, 1 site on IL-12R1, and 1 site on IL12R2). Using the published structure of 
IL-12 and predicted structures for each receptor subunit, we developed a model of the IL-12/IL-
12R complex (Fig. 3.6). By measuring distances between heparin binding domains on different 
subunits, we determined that only longer chains of heparin could span multiple domains. This 
finding agreed with our bioactivity studies and suggests that heparin may be facilitating 
enhanced bioactivity by stabilizing the IL-12/IL-12R complex. 
In addition to enhancing IL-12 activity on wild-type cells, our previous work also showed 
that heparin can rescue IL-12 signaling in cells producing mutant forms of IL-12 receptors (12). 
Therefore, bioactivity data in both wild-type and mutant cells imply that heparin serves as a co-
receptor for IL-12.  
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Previous studies have shown that IL-12R1 is the subunit mainly accountable for binding 
of IL-12, whereas IL12R2 plays a vital role in triggering the signaling functions of IL-12 (13, 
14). Indeed, by using Ba/F3 cell line as the host cell for expression of IL-12R1, IL-12R2 or 
IL-12R1 and IL-12R2 receptors, IL-12 was shown to signal through the single expression of 
IL-12R2 but not IL-12R1  (10). In another study supporting cytokine signaling through a 
single chain, , IL-22 was shown to form dimers/tetramers and bind to two single IL-22R1 
receptor chains (15), whereas this cytokine conventionally binds to two heterodimeric receptors, 
IL-10R1 and IL-22R1 (16). Yet another study showed that IL-35, a member of IL-12 family, was 
able to signal through a single receptor chain, with IL-12R2 alone inducing phosphorylated 
STAT4, or gp130 alone inducing phosphorylated STAT1 (17).  
Based on our data demonstrating that heparin facilitates IL-12 signaling in IL-12R1 
deficient cells as well as the single receptor chain signaling studies cited above, we developed 
two hypotheses: (1) heparin stabilizes binding between IL-12 and mutant expressed forms of IL-
12R1; and (2) heparin enhances binding between IL-12 and IL-12R2 allowing IL-12 to signal 
through only one receptor subunit.  
To test these hypotheses, we investigated the effect of heparin on IL-12 bioactivity in 2 
cell-based models including engineered NK-92MI cells producing mutant forms of IL-12R1 
and MSMD patient cells that are deficient in IL-12R1 expression. Engineered NK-92MI cells 
producing mutant forms of IL-12R1 are necessary for this study because: [1] we can have an 
unlimited supply of mutant cells that are essential for numerous planned studies, [2] we can have 
a library of IL-12R1 mutations that are important for determining the specific effect of heparin 
on IL-12 bioactivity in each type of mutation, and [3] we can correlatively compare the effect of 
heparin on IL-12 bioactivity between engineered NK-92MI cells and MSMD patient cells. IL-
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12R1 mutant NK-92MI cells were generated via CRISPR/Cas9 genomic editing technology. 
Loss of functional IL-12R1 and subsequent restoration of IL-12 signaling in the presence of 
heparin was confirmed in IL-12 bioactivity assays. IL-12R1 expression in different clones were 
examined via flow cytometry. Polymerase chain reaction (PCR) and Sanger sequencing were 
employed to characterize CRISPR/Cas9 induced mutations. IL-12 bioactivity, in the presence 
and absence of heparin, in peripheral blood T cells from 6 MSMD patients was also evaluated.  
Materials and Methods 
Cell culture and activation of MSMD peripheral blood mononuclear cells (PBMCs) 
The IL-2-independent, IL-12-responsive human natural killer cell line, NK-92MI 
(ATCC; CRL-2408TM), was cultured in complete media consisting of Alpha MEM 
supplemented with 12% FBS, 12% horse serum, 100 U/mL penicillin/streptomycin, 0.2 mM 
inositol, 0.02 mM folic acid, and 0.1 mM 2-mercaptoethanol.  
PBMCs from 9 MSMD patients were kindly provided by Dr. Jean-Laurent Casanova 
(Rockefeller University, NY). Mutations in IL12Rβ1 coding genes of those patients are 
described in Table A1.1 and Fig. A.1.1. 
PBMCs were activated by incubating 106 cells/ml with anti-CD3, anti-CD28 coated 
superparamagnetic beads (Dynabeads® Human T-Activator CD3/CD28; ThermoFisher) in 
culture media at a bead:cell ratio of 1:1 for 3 days. 
CRISPR/Cas9-mediated deletion of IL12Rβ1 
A 20-bp guide sequences (5’- GGAGCACTCGTAACGATCAC -3’) targeting DNA 
within the exon 3 of IL12Rβ1 gene was selected from “The CRISPR design tool” provided by 
Zhang lab, MIT (http://crispr.mit.edu/). Exon 3 of IL-12R1 gene was targeted for knocking-out 
this gene because it codes for the cytokine binding region of IL12Rβ1 gene that plays important 
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role in the interaction of IL-12 and its receptors. The single-guide RNA was picked based on the 
high quality of guiding to IL12Rβ1 coding gene and minimized off-target binding on other sites 
in the human genome. Then, a plasmid containing this single-guide RNA was purchased from 
Origene (pCas-Guide-EF1a-GFP, Origene). Plasmids were amplified by E. coli and then purified 
using QIAGEN Plasmid Maxi Kit. 
NK-92MI cells (2x106 cells) were re-suspended in 100 μl of electroporation buffer 
(Harvard Apparatus, Holliston, MA) and added to an electroporation cuvette. Plasmid (10 μg) was 
added to the electroporation cuvette and mixed well by pipetting. The cell suspension was 
electroporated with 250 volts, 25 ohms, and 750 μF in a 2 mm cuvette using the electroporation 
system ECM630 (Harvard Apparatus, Holliston, MA). Electroporated cells were then transferred 
to pre-warmed 1 ml culture media in a well of 6-well plate. These cells were cultured at 37oC for 
72 hours. 
NK-92MI transfected cells were harvested by centrifugation and diluted to a 
concentration of 2x106 cells/ml in PBS. Then, the cells were filtered through a 50μm filter into a 
FACS tube. The transfected cells were sorted using FACS Aria III system (BD Biosciences). 
Only the top 5% of GFP-positive cells were collected to ensure high transfection levels of 
CRISPR/Cas9 complexes.  
Cloning and sub-cloning selection of IL-12R1 engineered mutant NK-92MI cells 
Transfected cells were first cloned using a limiting dilution-based method. Cells were 
seeded in a 24-well plate with cell numbers of 50 cells/well. This concentration was used 
because the viability of this cell line is significantly reduced when they are seeded at extreme 
low density. Cells were cultured at 37°C, 5% CO2 for 10 - 14 days. Colonies were picked and 
dispersed into the appropriate liquid growth medium for further expansion and testing. 
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For sub-cloning selection, cells were added to a mixture of base methylcellulose medium 
ClonaCell Flex (#03818, Stemcell Technologies) and culture media with the concentration of 
100 cells/mL. Using a 12 mL syringe and a 16-gauge Blunt-End Needle (Catalog #28110), cell 
suspension was plated into a 100 mm Petri dishes and cultured at 37°C in a humidified 
atmosphere containing 5% CO2 for 10 - 14 days without disturbing the plates. Colonies were 
picked and dispersed into the appropriate liquid growth medium for further expansion and 
testing. 
IL-12 bioactivity assay 
To assess the effect of heparin on IL-12 bioactivity in IL-12R1 deficient cells, MSMD 
patient PBMCs, parental NK-92MI and IL12Rβ1 mutant cells were cultured with fixed or 
increasing concentrations of IL-12 (0, 200, 1000, 5000 pg/mL) ± 10 μg/ml heparin for 24 hours 
or 48 hours. IFN-γ production was quantified by ELISA. 
Polymerase chain reaction and Sanger sequencing analysis of IL12Rβ1 
Genomic DNA (gDNA) was extracted using QIAamp DNA Mini Kit (51304, Qiagen). 
Fifty nanograms of gDNA was then used for polymerase chain reaction (PCR) to amplify the 
sequence of exon 3, IL12Rβ1 gene. The sequence of primers used were as follows: (1) exon 3 – 
IL12Rβ1 → forward primer 5’- GGAGGGTTTAGGCTGAGGTG-3’ and reverse primer 5’- 
ATCACGCATCCGAGAGTAGG-3’; (2) 2871 base pairs (bp) amplicon → forward primer: 5' -
GAGGGCTGATGATCACTTGG - 3' and reverse primer: 5' - 
GCTAGTAGTATCAAGTCCCTTGCC - 3'; (3) 9499 bp amplicon → forward primer: 5' - 
CCTTGCTCAGCTTCAATGTG - 3' and reverse primer 5' - GGGACAGATGCAGAGATGG 
(18). PCR products were submitted to NCSU Genomic Sciences Laboratory for Sanger 
sequencing. 
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Flow cytometry analysis 
Expression of CD56 and IL-12R1 were analyzed using flow cytometry. Mutant and 
wild-type NK-92MI cells were stained with 1 μg/106 cells of PerCP-Cy5.5 mouse anti-human 
CD56, clone B159 (560842, BD Biosciences) or PerCP-Cy5.5-conjugated mouse IgG1, k isotype 
control (550795, BD Biosciences); APC mouse anti-human IL12Rβ1, clone 2.4E6 (558708; BD 
Biosciences), or APC-conjugated mouse IgG1, k isotype control (550854; BD Biosciences). 
Cells were rinsed twice in cold PBS and read on a BD FACSCelesta. Data were analyzed using 
FlowJo v10 software package (Flow Jo LLC, Ashland, OR). 
For intracellular staining, protein transport inhibitor containing monensin (554724, BD 
Biosciences) was added to the cells during treatment with media alone, heparin alone (10 
g/mL), IL-12 alone (200 pg/mL), or IL-12 (200 pg/mL) plus heparin (10 g/mL). Cells were 
fixed in Fixation/Permeabilization Solutions (554714 or 554655, BD Biosciences) using the 
manufacturer’s recommended protocols. Anti-human IFN BV421 (clone: B27) or mouse anti-
Stat4 (pY693) PE (clone 38/p-Stat4) were used for intracellular IFN and pSTAT4 staining. For 
pSTAT4 staining, permeabilization was performed using Perm Buffer III (558050, BD 
Biosciences). Data were acquired using a BD FACSCelesta flow cytometer (BD Biosciences) 
and analyzed using FlowJo software package (Flow Jo LLC, Ashland, OR). 
Results 
Generation of IL-12R1 functionally deleted NK-92MI cells 
 Because IFN- is the primary downstream product of IL-12, we measured IFN- 
production as a readout of IL-12 bioactivity. Initial studies showed that 4 different clones of IL-
12R1 mutant NK-92MI cells responded to IL-12 (Fig. A.1.2) by producing different levels of 
IFN-. Clone 6 was selected for further study due to its low responsiveness to IL-12. Although 
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studies with 200 pg/ml indicated that IL-12R1 was completely non-functional, when IL-12 
concentration was increased (1000 pg/mL), higher levels of IFN- production were observed. 
This indicated that clone 6 may not be a true clonal population, but rather a mixture of knocked-
out cells and wild-type cells. Therefore, we decided to subclone clone 6 using semi-solid 
methylcellulose medium. Most of the 9 subclones obtained did not respond to IL-12 at the dose 
of 200 pg/mL and only produced IFN- in response to IL-12 at 1000 pg/mL (Fig. A.1.3A). 
Subclone 7 did not respond to IL-12 even at the higher dose, however, this subclone produced a 
modest level of IFN- (266.748  3.45 pg/mL) when treated with 5000 pg/mL of IL-12 (Fig. 
A.1.3B). In contrast, the wild-type NK-92MI cells produced 1271.61  60.86 pg/ml of IFN- in 
response to 200 pg/mL of IL-12. For all IL-12R1 mutant cells, heparin appeared to at least 
partially recover the bioactivity of IL-12. 
Immunophenotyping studies revealed that subclone 7 expressed lower levels of not only 
IL-12R1, but also CD56, pSTAT4, and IFN- compared to wild-type NK-92MI cells (Fig. 
A.1.4).The CRISPR/Cas9 approach used in this study, utilized non-homologous end-joining to 
rejoin DNA strands after double strand breaks. Thus, Sanger sequencing was employed to 
determine the nature of the mutations induced by CRISPR/Cas9. The amplification of a 319 bp 
region around the Cas9 cut site in exon 3 of the gene encoding IL-12R1, from each of the 
subclones, produced a single clear band visualized by gel electrophoresis (Fig. A.1.5A). 
Sequencing PCR products revealed that exon 3, in mutant clones was intact and identical to wild-
type cells (Fig. A.1.5B). In an attempt to look for larger insertion or deletions, PCR of exon 3 
from subclone 7 cells was repeated using additional primers. These primers produced amplicons 
of 2871 bp and 9499 bp with no other significant gene PCR products. Thus, sequencing and PCR 
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analyses were unsuccessful at identifying a significant genomic alteration compared to wild-type 
cells (Fig. A.1.5C). 
Effect of heparin on IL-12 bioactivity in PBMCs isolated from MSMD patients 
 Activated PBMCs from 6 out of 9 MSMD patients were evaluated for IFN- production 
in response to IL-12 alone or IL-12 plus heparin. Three patient samples were not evaluable due 
to insufficient cell numbers or contamination. Four of the six evaluable samples tested 
demonstrated a measurable increase in IFN- when heparin was included (Fig. A.1.6). Increases 
ranged from 17.76% in patient 006193 to 40.3% in patient 04893. Heparin had no effect on two 
MSMD patient samples. A cursory analysis relating the type or location of mutation (Table 
A.1.1) and the heparin-enhanced IL-12 activity revealed no obvious correlation. 
Discussion 
The data presented above confirmed our previous data that heparin can enhance IL-12 
signaling in IL-12R1 deficient cells. However, neither of the hypothetical mechanisms for the 
enhanced activity could be confirmed or refuted. 
IL-12 bioactivity studies in IL-12R1 mutant NK-92MI cells demonstrated that different 
clones responded differently to IL-12. Our initial interpretation of these data was that 
CRISPR/Cas9 randomly induced mutations in the sequence of exon 3 of IL-12R1 which led to 
the expression of various IL-12R1 mutant receptors. Cells with minor mutations in IL-12R1 
were expected to have higher levels of responsiveness to IL-12. However, PCR and sequencing 
experiments could not detect a mutation in the region of exon 3 of IL-12R1. Because 
CRISPR/Cas9 might produce large insert/deletion fragments around exon 3, we tried to broaden 
the amplification around the  exon 3 cut site using different primers. Unfortunately, the results of 
these amplifications did not reveal any differences in PCR products between mutant cells and 
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wild-type cells. In addition, sequencing data indicated that exon 3 in all subclones was identical 
to the wild-type version.  
Although PCR and sequencing could not detect a mutation, IL-12R1 expression levels, 
as assessed via flow cytometry were markedly reduced. As such, these mutant cells may still be 
considered as IL-12R1-deficient. Given that CD56 and phosphorylated STAT4 were also 
decreased in NK-92MI mutants, it is possible that the CRISPR/Cas9 protocol induced unknown 
off-target effects. Nevertheless, heparin was still able to partially recover IL-12 signaling in these 
cells.  
Studies of IL-12 bioactivity in MSMD patient cells revealed that heparin enhanced IL-12-
induced production of IFN- in 4 of 6 patients. Notably, 2 of the patient samples that exhibited 
improved IL-12 signaling in the presence of heparin contained a point mutation which induced 
transcription of a stop codon. For instance, the genetic sequence of patient 004893 indicates 
substitution of a stop codon in exon 3 instead of a glutamine at position 32. Patient 013315 has a 
similar stop codon in exon 7. These mutations are located in the extracellular domain of IL-
12R1 and produce undetectable expression of IL-12R1 as confirmed by other groups (8, 19). 
A complete IL-12R1 knockout would seem to favor our second hypothesis that heparin 
facilitates IL-12 signaling through IL-12R2 exclusively. However, according to Dr. J.-L. 
Casanova, a leading expert in MSMD and the provider of these cells, it is possible for cells to 
‘read through’ the stop codon, thus producing the wild-type IL-12R1. This ‘leakiness’ is very 
rare but could happen in a very small percentage of cells, likely less than 1 percent, that would 
not be detectable or impart clinical benefit. Nevertheless, a small number of ‘leaky’ cells could 
account for heparin-enhanced IL-12 signaling and does not allow for exclusion of any of our 
previous hypotheses.  
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The above discussion pertains to mutations in which a stop codon terminates the 
translation of IL-12R1 thus resulting no expression of the receptor subunit. It should be noted 
that a subset of MSMD patients have mutations resulting in truncated IL-12R1. We have 
requested, but have not received, MSMD patient  samples with specific truncated forms of IL-
12R1, to determine if heparin can rescue IL-12 activity in patients with this genotype.  
Conclusions and Future Studies 
 This study was our initial attempt to explain the effect of heparin on IL-12 bioactivity in 
IL-12R1 deficient cells. We showed that heparin slightly recovered the production of IFN- in 
response to IL-12 in PBMCs isolated from 4 of 6 MSMD patients. This result appears to support 
the hypothesis that recovery of IL-12-induced IFN- production in MSMD patient PBMCs by 
heparin likely occurred by signaling via the intact IL-12R2 receptor. However, due to the 
potential ‘leakiness’ of wild-type IL-12Rb1 expression, we could not confirm this hypothesis.  
We also found that heparin helped recover the bioactivity of IL-12 in multiple clones of 
IL-12R1 engineered mutant NK-92MI cells. However, the effect of heparin plus IL-12 in these 
cell clones was not definitive because impairment of IL-12 signaling in these cells were possibly 
explained by the off-target activity of CRISPR/Cas9. In this study, we delivered DNA plasmids 
coding for CRISPR/Cas9 complex that was not ideal for precise genome editing. Continuous 
expression of Cas9 nuclease by DNA plasmid increased the potential for undesired off-targets 
and mutations. Moreover, there was a high possibility that DNA plasmids might be integrated 
within the chromosome leading to stable expression of Cas9. In future experiments, Cas9 protein 
or Cas9 mRNA can be introduced to reduce off-target effects. Furthermore, we can improve the 
editing fidelity of CRISPR/Cas9 technology by using homology-directed repair (HDR) that 
provides a DNA template with homology to the sequence flanking double strand break (DSB) 
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location. HDR is a more precise mechanism for double strand break editing due to the use of 
higher sequence homology between the damaged and intact donor strands of DNA. Using the 
HDR approach will also allow for the generation of a library of mutants with known mutations at 
various locations in the IL-12R1 gene. Some of these mutations will be matched with known 
mutations in MSMD patients. Additional future studies are described in Chapter 4. 
 
  
144 
Table A.1.1. Genetic status of MSMD patient samples 
Patient code$ Gender Origin Gene Phenotype Genetic status 
004893 F France IL-12R1 Patient p.Q32X/p.Q32X 
006193 M Morocco IL-12R1 Patient c.1791+2T>G/c.1791+2T>G 
009203 M Poland 
IL-12R1 
Patient 
p.Q32*/WT and 
c.1189+2T>A/WT 
013315 M Morocco IL-12R1 Patient p.R211X/p.R211X 
004013 F Mexico 
IL-12R1 
Patient 
deletion exon 8/WT and  
p.R521X/WT 
012183 M N/A IL-12R1 Patient c.783+1G>A/c.783+1G>A 
001043 F Turkey IL-12R1 Patient p.R486X/R486X 
004632 M Turkey IL-12R1 Patient p.R486X/p.R486X 
008404 M France IL-12R1 Patient p.Q32X/c.1623_1624delinsT 
 
$ Bold and italic font: Patient cells that responded with IL-12 and heparin 
Italic font: Patient cells that did not respond with IL-12 and heparin 
Underline font: Patient cells that did not expand after stimulation 
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Figure A.1.1. Mutation locations in IL-121 gene of MSMD patients. Green boxes show 
mutation locations in IL-12R1 gene of MSMD patients used in this study. IL-12R1 gene 
includes 17 exons (numbered 1 to 17 in this graph), in which exon 1 codes for a signal peptide, 
exon 2 – 13 code for the extracellular domain, exon 14 codes for the transmembrane domain, 
exon 15 – 17 code for the intracellular domain. 
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Figure A.1.2. IL-12 bioactivity assays on NK-92MI cells (clones and wild-type cells). 
The production of IFN-𝛾 by (A) NK-92MI cell clones or (B) NK-92MI clone 6 cells vs. wild-
type cells was measured after 24-hour exposure to a fixed concentration of IL-12, 200 pg/ml for 
(A) or increasing doses of IL-12 for (B). Heparin concentration was used at a fixed concentration 
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of 10 g/mL. IFN𝛾 concentrations were measured via ELISA. (A) The comparison of IL-12 
responsiveness in mutant NK-92MI cell clones to media vs. IL-12 alone via t test (***p<0.0001, 
*p<0.05 via t-test). (B) Heparin enhanced the bioactivity of IL-12 in mutant NK-92MI cells and 
wild-type NK-92MI cells (***p<0.0001 via two-way ANOVA). Tukey’s posttest was used to 
distinguish the difference of IL-12 activity in specific concentration of IL-12 vs. IL-12 plus 
heparin (dashed line, ***p<0.0001). Data points represent mean ± standard deviation of triplicate 
measurements. Experiments were performed in triplicate and repeated three times with similar 
results. 
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Figure A.1.3. IL-12 bioactivity assays on NK-92MI cells (sub clones and wild-type 
cells). The production of IFN-𝛾 by NK-92MI subcloned cells vs. wild-type cells was measured 
after 24-hour exposure to (A) fixed dose of IL-12 (200 pg/mL) or (B) and (C) increasing doses of 
IL-12 from 0 pg/mL to 1000 pg/mL (B) or from 0 pg/mL to 5000 pg/mL (C). Heparin 
concentration was used at a fixed concentration of 10 g/mL. IFN𝛾 concentrations were 
measured via ELISA. For statistical analyses, heparin enhanced the bioactivity of IL-12 in 
mutant NK-92MI cells (***p<0.0001 vs. IL-12 alone via two-way ANOVA, solid line). Tukey’s 
posttest was used to compare the production of IFN- in response to IL-12 alone vs. IL-12 plus 
heparin at each specific IL-12 concentration (dashed line, ***p<0.0001), ns: not significant. Data 
points represent mean ± standard deviation of triplicate measurements. Experiments were 
performed in triplicate and repeated three times with similar results.  
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Figure A.1.4. Expression of CD56, IL-12R1, pSTAT4, IFN- in mutant (subclone 7) and 
wild-type NK-92MI cells. Dot plots show representative expression of (A) CD56, (B) IL12R1, 
(C) pSTAT4, (D) IFN- by mutant NK-92MI cells and wild-type NK-92MI cells. (A) Cells were 
stained using PerCP-Cy5.5 mouse anti-human CD56 (clone B159) or PerCP-Cy5.5-conjugated 
mouse IgG1, k isotype control. (B) Cells were stained using APC mouse anti-human IL12Rβ1, 
(clone 2.4E6) or APC-conjugated mouse IgG1, k isotype control. (C). Cells were stained using 
PE mouse anti-Stat4 (pY693) (clone 38/p-Stat4) or PE-conjugated mouse IgG2b, k isotype 
control. (D) Cells were stained using BV421 mouse anti-human IFN (clone: B27) or BV421-
conjugated mouse IgG1, k isotype control. In (C) and (D), cells were stimulated by media, 
heparin alone (10 g/mL), IL-12 alone (200 pg/mL), or both IL-12 (200pg/mL) and heparin (10 
g/mL) for 15 minutes (C) or 12h (D) before performing intracellular staining. (E) Dot plots 
describe positive percentages of CD56, IL-12R1, pSTAT4 (under induction of IL-12 and 
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heparin), and IFN- (under induction of IL-12 and heparin) in mutant NK-92MI cells (subclone 
7) and wild-type NK-92MI cells (**p<0.01, ***p<0.001, ****p<0.0001 via two-tailed t test). 
Data were acquired using a FACSCelesta cytometer, and analyzed by FlowJo software. 
Experiments were performed in triplicate and repeated three times with similar results. 
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Figure A.1.5. Amplification and sequencing of exon 3, IL12R1 gene of mutant and wild-
type NK-92MI cells. (A) PCR products of exon 3, IL12R1 amplified from genomic DNA of 
subclone 5 (lane 2), subclone 6 (lane 3), subclone 7 (lane 4), subclone 8 (lane 5), clone 6 (lane 
6), and wild-type cells (lane 7). (B) Sequencing comparison at CRIPSR/Cas9-targeting 
sequences (5’-GTGATCGTTACGAGTGCTCC-3’) located on exon 3, IL-12R1 gene of 
subclone cells and wild-type cells. (C) Map of amplifications in IL-12R1 gene. (D) PCR 
products of 2871-bp (lane 1 and lane 4), 9499 bp (lane 2 and lane 5), and 319 bp (lane 3 and lane 
156 
6) amplifications in exon 3, IL-12R1 gene of subclone 7 (lane 1 - 3) and wild-type cells (lane 4 
- 6). (E) PCR products of 2871-bp amplification in exon 3, IL-12R1 gene of subclone 7 (lane 1) 
and wild-type cells (lane 2). (D) annealing temperature was set at 62.4 C. (E) annealing 
temperature was set at 64.4 C. 
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B (cont.) 
  
 
 
 
Figure A.1.6. The effect of heparin on IL-12 bioactivity on MSMD patient PBMCs. The 
production of IFN- produced by MSMD patient PBMCs in response to IL-12 alone and IL-12 
plus heparin in (A) the first batch (patient 4893, 13315, and 12183) or (B) the second batch 
(patient 6193, 4013, 9203). (C) The production of IFN- 2 healthy donors and 3 MSMD patients 
of the first batch that were induced by PMA/Ionomycin. IFN- production was measured after 
48-hour exposure to increasing concentrations of IL-12 for (A and B) or a fixed concentration of 
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PMA/Ionomycin (0.08 M PMA and 1.34 M Ionomycin) for (C). Heparin concentration was 
fixed at 10 g/mL. IFN- concentrations were measured via ELISA. For global response of 
patients, treatment of heparin and IL-12 showed no recovery of IL-12 bioactivity in comparison 
with IL-12 alone (p>0.5 via two-way ANOVA, solid line). For particular analysis on each 
patient, heparin slightly recovered the bioactivity of IL-12 in PBMCs isolated from two MSMD 
patients (*p<0.05 vs. IL-12 alone via two-way ANOVA, solid line – patient 4893 and **p<0.01 
vs. IL-12 alone via two-way ANOVA, solid line – patient 13315, *p<0.05 vs. IL-12 alone). 
Tukey’s posttest was used to compare the production of IFN- in response to IL-12 alone vs. IL-
12 plus heparin at each specific IL-12 concentration (dashed line, *p<0.05, **p<0.01). Heparin 
did not recover IL-12 bioactivity in patient 12183 and patient 9203 (p>0.05 vs. IL-12 alone via 
two-way ANOVA, solid line). Data points represent mean ± standard deviation of triplicate 
measurements. Three experiments were repeated with similar results. 
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APPENDIX 2: THE ENHANCING EFFECT OF HEPARIN ON MOUSE IL-23 
BIOACTIVITY 
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Appendix 2. The enhancing effect of heparin on mouse IL-23 bioactivity. The production of 
(A) alkaline phosphatase by HEK-BlueTM IL-23 cells or (B) mouse IL-17A by splenocytes 
isolated from C57BL/6J mouse was measured after exposure to a fixed concentration of mIL-23 
(5 ng/mL) for (A) or a range of mouse IL-23 concentration for (B). Heparin was used at a fixed 
concentration of 10 g/mL. Purified mouse IL-23 is the recombinant protein purified by our lab. 
Positive control of mouse IL-23 (rIL-23) is the commercial recombinant protein from market 
place. Production of alkaline phosphatase was measured by a colorimetric assay that detects the 
colored product converted by alkaline phosphatase. Mouse IL-17A was measured via ELISA. 
Heparin enhances the bioactivity of mouse IL-23 in HEK-BlueTM IL-23 cells and C57BL/6J 
splenocytes (***p<0.05 via two-tailed t test). 
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APPENDIX 3: THE INHIBITORY EFFECT OF P40 ON IL-12 BIOACTIVITY IS 
REDUCED BY HEPARIN 
 
 
 
 
Appendix 3. The inhibitory effect of p40 on IL-12 bioactivity is reduced by heparin. The 
production of (A) alkaline phosphatase by HEK-BlueTM IL-12 cells was measured after exposure 
to a fixed concentration of IL-12 (1000 pg/mL) and a fixed concentration of heparin (10 g/mL) 
with a range concentrations of mouse p40 monomer, p40 dimer. Production of alkaline 
phosphatase was measured by a colorimetric assay that detects the colored product converted by 
alkaline phosphatase. Heparin reduced the inhibitory effect of p40 on IL-12 bioactivity in HEK-
BlueTM IL-23 cells (***p<0.0001 via two-way ANOVA, solid line), ns: not significant. Tukey’s 
posttest was used to compare the reduction of p40 inhibitory effect on IL-12 bioactivity by 
heparin at specific p40 concentration (dashed line, ***p<0.0001). 
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